Cellectis SA Sponsored ADR Aktienkurs
Ist Cellectis SA Sponsored ADR eine Topscorer-Aktie nach der Dividenden-, High-Growth-Investing- oder Levermann-Strategie?
Als kostenloser aktien.guide Basis-Nutzer kannst Du die Scores zu allen 9.086 weltweiten Aktien einsehen.
aktien.guide Premium
aktien.guide Unlimited
Kennzahlen
📘 Marktkapitalisierung
📈 Was ist das?
Die Marktkapitalisierung zeigt, wie viel ein Unternehmen laut Börse aktuell wert ist.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Sie hilft Unternehmen in Größenklassen (Large, Mid, Small Cap) einzuordnen und gibt Hinweise auf Marktmacht und Stabilität.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Große Unternehmen gelten als stabiler, zahlen oft Dividenden, wachsen aber langsamer.
- Kleine Firmen können stärker wachsen, sind aber schwankungsanfälliger.
- Die Marktkapitalisierung ist ein guter Indikator für Unternehmensgröße, aber kein Maß für Unter- oder Überbewertung.
📘 Enterprise Value (Unternehmenswert)
📈 Was ist das?
Der Enterprise Value (EV) zeigt, was ein Unternehmen tatsächlich kostet, wenn man es komplett übernehmen würde – inklusive Schulden und abzüglich Cash.
🧮 Wie wird es berechnet?
(= Marktkapitalisierung + Nettoverschuldung)
🏛️ Wofür ist es wichtig?
Der EV ist eine realistischere Bewertungsbasis als die Marktkapitalisierung, da er die Kapitalstruktur berücksichtigt. Er ist Grundlage für Kennzahlen wie EV/FCF oder EV/Sales.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Der Enterprise Value zeigt, was ein Unternehmen tatsächlich wert ist – unabhängig davon, wie es finanziert ist.
- Er ist besonders wichtig für professionelle Investoren, da er eine objektivere Grundlage für Bewertungsvergleiche bietet als die Marktkapitalisierung allein.
- Ein Unternehmen mit hoher Verschuldung erscheint im EV teurer, eines mit viel Cash günstiger – auch wenn sie an der Börse gleich viel wert sind.
📘 Nettoverschuldung
📈 Was ist das?
Die Nettoverschuldung zeigt, wie viele Schulden nach Abzug des verfügbaren Cashs tatsächlich verbleiben.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Sie zeigt, wie stark ein Unternehmen von Fremdkapital abhängig ist – und wie gut es in der Lage ist, seine Schulden kurzfristig zu bedienen.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine niedrige oder negative Nettoverschuldung bedeutet hohe finanzielle Stabilität.
- Unternehmen mit viel Cash und geringer Verschuldung sind besser gerüstet für Krisen.
- Eine hohe Nettoverschuldung erhöht das Risiko – besonders bei steigenden Zinsen oder konjunkturellen Schwächen.
📘 Cash
📈 Was ist das?
Der Cashbestand zeigt, wie viele liquide Mittel einem Unternehmen sofort zur Verfügung stehen.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Er gibt Auskunft über die finanzielle Flexibilität: Ein hoher Cashbestand ermöglicht Investitionen, Rückkäufe oder Krisenresistenz.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher Cashbestand zeigt finanzielle Stärke und Handlungsspielraum.
- Cash kann für Investitionen, Schuldentilgung oder Aktienrückkäufe genutzt werden.
- Allerdings: Zu viel ungenutztes Kapital kann auch auf mangelnde Investitionsideen hinweisen.
📘 Anzahl ausstehender Aktien
📈 Was ist das?
Die Anzahl ausstehender Aktien gibt an, wie viele Aktien eines Unternehmens aktuell im Umlauf sind und von Investoren gehalten werden.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Sie ist die Grundlage für viele Kennzahlen wie Gewinn je Aktie (EPS), Marktkapitalisierung oder KGV.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Je weniger Aktien im Umlauf sind, desto höher fällt z. B. der Gewinn je Aktie aus – wichtig für Bewertung und Dividendenrendite.
- Aktienrückkäufe verringern die Anzahl ausstehender Aktien – und steigern den Wert je Aktie.
- Kapitalerhöhungen haben den gegenteiligen Effekt: mehr Aktien → Verwässerung der bestehenden Anteile.
📘 Kurs-Gewinn-Verhältnis (KGV)
📈 Was ist das?
Das KGV zeigt, wie oft der Gewinn pro Aktie im aktuellen Aktienkurs enthalten ist – also wie „teuer“ eine Aktie im Verhältnis zum Gewinn ist.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Das KGV gehört zu den bekanntesten Bewertungskennzahlen. Es hilft Anlegern einzuschätzen, ob eine Aktie im Vergleich zu ihrem Gewinn eher günstig oder teuer erscheint.
🧮 Berechnung
📊 KGV (TTM) = bezogen auf den Gewinn der letzten 12 Monate (Trailing Twelve Months):🎯 Was bedeutet das für Anleger?
- Ein niedriges KGV kann auf eine günstige Bewertung hindeuten – oder auf Probleme im Geschäftsmodell.
- Ein hohes KGV kann Wachstumserwartungen widerspiegeln – oder eine überbewertete Aktie.
📘 Kurs-Umsatz-Verhältnis (KUV)
📈 Was ist das?
Das KUV zeigt, wie viel Anleger für 1 € Umsatz eines Unternehmens zahlen – unabhängig vom Gewinn.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Das KUV ist besonders bei wachstumsstarken oder noch nicht profitablen Unternehmen hilfreich. Es zeigt, wie hoch der Umsatz an der Börse bewertet wird.
🧮 Berechnung
Marktkapitalisierung = 77,77 Mio. $ | Umsatz (TTM) = 76,81 Mio. $
Marktkapitalisierung = 77,77 Mio. $ | Umsatz erwartet = 57,97 Mio. $
🎯 Was bedeutet das für Anleger?
- Ein niedriges KUV kann auf Unterbewertung hindeuten – oder auf schwache Margen.
- Ein hohes KUV kann hohe Erwartungen widerspiegeln – oder übermäßigen Optimismus.
- Besonders sinnvoll bei Wachstumsunternehmen, bei denen der Gewinn oder Free Cashflow (noch) keine Aussagekraft hat.
📘 Unternehmenswert zu Umsatz (EV/Sales)
📈 Was ist das?
EV/Sales zeigt, wie viel Anleger für 1 € Umsatz eines Unternehmens zahlen, wenn man auch Schulden und Cash berücksichtigt – es ist eine kapitalstrukturbereinigte Version des KUV.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Diese Kennzahl eignet sich besonders für den Vergleich von Unternehmen mit unterschiedlicher Verschuldung – sie zeigt, wie teuer ein Unternehmen tatsächlich im Verhältnis zum Umsatz ist.
🧮 Berechnung
Enterprise Value = 25,92 Mio. $ | Umsatz (TTM) = 76,81 Mio. $
Enterprise Value = 25,92 Mio. $ | Umsatz erwartet = 57,97 Mio. $
🎯 Was bedeutet das für Anleger?
- EV/Sales ist neutral gegenüber der Kapitalstruktur und eignet sich gut für Unternehmensvergleiche.
- Ein niedriges Verhältnis kann auf eine günstig bewertete Aktie hindeuten – ein hohes Verhältnis auf hohe Erwartungen oder Überbewertung.
- Besonders nützlich bei wachstumsstarken, noch nicht profitablen Firmen.
📘 Unternehmenswert zu Free Cashflow (EV/FCF) | ex SBC
📈 Was ist das?
EV/FCF setzt den Unternehmenswert eines Unternehmens ins Verhältnis zu seinem Free Cashflow. Die Kennzahl zeigt damit, mit welchem Vielfachen des aktuellen Free Cashflows ein Unternehmen bewertet wird. EV/FCF ex SBC berücksichtigt zusätzlich aktienbasierte Vergütungen (Stock-Based Compensation, SBC). SBC verursacht zwar keinen direkten Cash-Abfluss, kann bestehende Aktionäre jedoch durch die Ausgabe zusätzlicher Aktien verwässern. Deshalb wird SBC bei dieser Variante vom Free Cashflow abgezogen.
🧮 Wie wird es berechnet?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cashflow (TTM) − SBC)
🏛️ Wofür ist es wichtig?
EV/FCF ermöglicht eine Bewertung auf Basis des Free Cashflows und ergänzt damit gewinnbasierte Bewertungskennzahlen wie das KGV. Die Variante ex SBC berücksichtigt zusätzlich die wirtschaftliche Belastung durch aktienbasierte Vergütungen und ermöglicht dadurch eine konservativere Betrachtung aus Sicht der Aktionäre.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein niedriges EV/FCF bedeutet, dass der Unternehmenswert im Verhältnis zum aktuellen Free Cashflow niedrig ist. Die Ursachen dafür sollten jedoch immer im Unternehmens- und Branchenkontext betrachtet werden.
- Ein hohes EV/FCF bedeutet, dass der Unternehmenswert im Verhältnis zum aktuellen Free Cashflow hoch ist. Das kann beispielsweise auf hohe Wachstumserwartungen oder eine vorübergehend schwache Cash-Generierung zurückzuführen sein.
- Bei positiver SBC und positivem bereinigtem Free Cashflow fällt EV/FCF ex SBC in der Regel höher aus als das klassische EV/FCF.
- Besonders aussagekräftig ist die Kennzahl bei Unternehmen mit relativ stabilen und gut einschätzbaren Cashflows.
- Bei negativem oder sehr niedrigem Free Cashflow ist EV/FCF nur eingeschränkt aussagekräftig und sollte nicht wie ein gewöhnliches Bewertungsmultiple interpretiert werden.
📘 Kurs-Buchwert-Verhältnis (KBV)
📈 Was ist das?
Das KBV zeigt, wie hoch der Marktwert eines Unternehmens im Verhältnis zu seinem bilanziellen Eigenkapital ist.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Das KBV ist besonders bei Substanzwerten (z. B. Banken, Industrie) relevant. Es hilft Anlegern zu erkennen, ob ein Unternehmen unter oder über seinem buchhalterischen Vermögen bewertet ist.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein KBV unter 1 kann auf Unterbewertung oder schwache Rentabilität hindeuten.
- Ein KBV über 1 zeigt, dass der Markt dem Unternehmen Mehrwert über den Buchwert hinaus zuschreibt (z. B. Marken, Patente, Wachstum).
- Das KBV eignet sich besonders gut für Unternehmen mit stabilen, materiellen Vermögenswerten.
📘 Eigenkapitalquote
📈 Was ist das?
Die Eigenkapitalquote zeigt, wie hoch der Anteil des Eigenkapitals an der Bilanzsumme eines Unternehmens ist – also wie stark es sich aus eigenen Mitteln finanziert.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Eine hohe Eigenkapitalquote steht für finanzielle Stabilität, Krisenfestigkeit und gute Bonität. Sie ist besonders relevant bei der Beurteilung der Verschuldung.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine hohe Eigenkapitalquote signalisiert finanzielle Stabilität – besonders in Krisenzeiten.
- Ein niedriger Wert kann auf ein höheres Risiko oder eine aggressive Verschuldung hinweisen.
- Wichtig: Die Eigenkapitalquote sollte immer gemeinsam mit der Eigenkapitalrendite betrachtet werden. Nur so lässt sich beurteilen, ob ein Unternehmen nicht nur solide, sondern auch effizient wirtschaftet.
📘 Eigenkapitalrendite (ROE)
📈 Was ist das?
Die Eigenkapitalrendite zeigt, wie effizient ein Unternehmen mit dem Kapital seiner Aktionäre arbeitet – also wie viel Gewinn es pro Euro Eigenkapital erwirtschaftet.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die Eigenkapitalrendite ist eine zentrale Rentabilitätskennzahl. Sie hilft Anlegern zu erkennen, ob das Unternehmen eine attraktive Verzinsung auf das eingesetzte Eigenkapital erwirtschaftet.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine hohe Eigenkapitalrendite spricht für ein starkes, effizientes Geschäftsmodell.
- Besonders interessant ist sie bei kapitalintensiven Firmen oder solchen mit hoher Eigenkapitalquote.
- Wichtig: Ein sehr hoher ROE kann auch auf hohe Schulden hinweisen – daher sollte sie immer im Kontext mit der Eigenkapitalquote betrachtet werden.
📘 Return on Capital Employed (ROCE)
📈 Was ist das?
ROCE misst die Gesamtrentabilität eines Unternehmens – also wie effizient es das eingesetzte Kapital (Eigen- und Fremdkapital) zur Gewinnerzielung nutzt.
🧮 Wie wird es berechnet?
Das eingesetzte Kapital ist das gesamte betriebsnotwendige Kapital, unabhängig von der Finanzierungsquelle.
🏛️ Wofür ist es wichtig?
ROCE eignet sich besonders gut für den Vergleich unterschiedlich finanzierter Unternehmen. Es zeigt, wie effektiv ein Unternehmen Kapital investiert – unabhängig von der Kapitalstruktur.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher ROCE zeigt, dass ein Unternehmen sein Kapital effizient einsetzt – unabhängig davon, ob es durch Eigen- oder Fremdkapital finanziert ist.
- Je höher der ROCE im Vergleich zu ähnlichen Unternehmen, desto mehr Wert schafft das Unternehmen mit seinem investierten Kapital.
- Besonders wichtig ist der ROCE bei Firmen mit hohen Investitionen – z. B. in Industrie, Energie oder Infrastruktur.
📘 Return on Invested Capital (ROIC)
📈 Was ist das?
ROIC zeigt, wie effizient ein Unternehmen das Kapital investiert, das langfristig im operativen Geschäft gebunden ist – unabhängig davon, ob es aus Eigen- oder Fremdkapital stammt.
🧮 Wie wird es berechnet?
- NOPAT = „Net Operating Profit After Taxes“
- Investiertes Kapital = operatives Vermögen abzüglich nicht-verzinster Schulden
🏛️ Wofür ist es wichtig?
ROIC ist eine der präzisesten Kennzahlen zur Bewertung der Kapitalrendite – besonders im Vergleich zur Eigenkapitalrendite, weil es Verzerrungen durch Schulden vermeidet. Er zeigt, ob ein Unternehmen Mehrwert für alle Kapitalgeber schafft.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher ROIC zeigt, wie gut ein Unternehmen mit dem tatsächlich investierten (betriebsnotwendigen) Kapital wirtschaftet.
- Im Unterschied zu ROCE wird nur Kapital betrachtet, das wirklich zur Finanzierung operativer Aktivitäten dient – und verzinst werden muss.
- Besonders hilfreich, um die Kapitalrendite von Unternehmen mit viel „überschüssigem“ Kapital oder zinsfreien Verbindlichkeiten realistisch zu vergleichen.
📘 Verschuldungsgrad (Leverage Ratio)
📈 Was ist das?
Der Verschuldungsgrad zeigt, wie stark ein Unternehmen durch verzinsliche Schulden (z. B. Kredite und Anleihen) im Verhältnis zum Eigenkapital finanziert ist.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die Kennzahl hilft, das finanzielle Risiko und die Abhängigkeit von Fremdkapital zu beurteilen. Ein hoher Verschuldungsgrad kann die Eigenkapitalrendite steigern – birgt aber auch erhöhte Risiken bei Zinsanstiegen oder Liquiditätsengpässen.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein niedriger Verschuldungsgrad steht für finanzielle Stabilität und Unabhängigkeit.
- Ein hoher Wert kann auf erhöhte Risiken hinweisen – insbesondere bei schwankenden Zinsen oder konjunkturellen Schwächen.
- Wichtig: Immer im Kontext zur Branche und Kapitalintensität bewerten.
📘 Umsatz
📈 Was ist das?
Der Umsatz zeigt, wie viel ein Unternehmen insgesamt mit seinen Produkten und Dienstleistungen verdient – also den Bruttoerlös vor Abzug von Kosten.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Der Umsatz ist eine der zentralen Kennzahlen zur Einschätzung der Unternehmensgröße, Marktstellung und Wachstumskraft.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein wachsender Umsatz zeigt eine steigende Nachfrage und kann ein guter Frühindikator für Gewinnsteigerungen sein.
- Vergleiche von aktuellem und erwartetem Umsatz geben Hinweise auf das Marktumfeld und Analystenerwartungen.
- Wichtig: Starker Umsatz allein genügt nicht – auch Margen und Profitabilität zählen.
📘 EBITDA
📈 Was ist das?
EBITDA steht für „Earnings Before Interest, Taxes, Depreciation and Amortization“ – also Gewinn vor Zinsen, Steuern und Abschreibungen. Es zeigt das operative Ergebnis eines Unternehmens, bereinigt um bilanztechnische und finanzierungsbedingte Effekte.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
EBITDA ist eine verbreitete Kennzahl zur Beurteilung der operativen Leistungsfähigkeit – insbesondere bei kapitalintensiven Unternehmen oder im internationalen Vergleich.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hohes oder wachsendes EBITDA spricht für starke operative Erträge – unabhängig von Bilanzierung oder Steuerlast.
- EBITDA ist besonders nützlich, um Unternehmen branchenübergreifend zu vergleichen.
- Wichtig: EBITDA ist keine offizielle Gewinnkennzahl – Abschreibungen und Finanzierungskosten werden ausgeklammert.
📘 EBIT
📈 Was ist das?
EBIT steht für „Earnings Before Interest and Taxes“ – also Gewinn vor Zinsen und Steuern. Es zeigt das operative Ergebnis eines Unternehmens nach Abschreibungen, aber vor Finanzierungs- und Steueraufwand.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
EBIT ist eine zentrale Kennzahl zur Beurteilung der Profitabilität aus dem Kerngeschäft – unabhängig von Kapitalstruktur oder Steuersystem.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hohes EBIT deutet auf ein profitables Kerngeschäft hin – vor Zinslasten oder steuerlichen Effekten.
- Es erlaubt objektivere Vergleiche zwischen Unternehmen mit unterschiedlicher Finanzierung.
- Im Vergleich mit EBITDA zeigt EBIT bereits den Einfluss von Abschreibungen auf das operative Ergebnis.
📘 Nettogewinn
📈 Was ist das?
Der Nettogewinn ist der verbleibende Jahresüberschuss (oder -fehlbetrag) eines Unternehmens – nach Abzug aller Kosten, Steuern, Zinsen und Abschreibungen
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Der Nettogewinn ist die zentrale Erfolgskennzahl – er zeigt, wie profitabel ein Unternehmen nach allen Kosten tatsächlich arbeitet.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein steigender Nettogewinn zeigt, dass das Unternehmen effizient wirtschaftet – trotz aller Kosten.
- Die Entwicklung des Gewinns beeinflusst z. B. direkt das KGV und weitere Kennzahlen.
- Im Zeitverlauf lässt sich ablesen, wie stabil und profitabel ein Geschäftsmodell wirklich ist.
📘 Free Cashflow (FCF) | ex SBC
📈 Was ist das?
Der Free Cashflow gibt an, wie viel Bargeld tatsächlich übrig bleibt, nachdem ein Unternehmen seine Betriebsausgaben und Investitionsausgaben gedeckt hat. Der FCF ex SBC zieht zusätzlich die aktienbasierte Vergütung ab, um den Cashflow um den Effekt der nicht zahlungswirksamen SBC zu bereinigen.
🧮 Wie wird es berechnet?
Free Cashflow ex SBC = Operativer Cashflow − SBC − Investitionen in Sachanlagen (CAPEX)
🏛️ Wofür ist es wichtig?
Der FCF spiegelt die tatsächliche Finanzkraft eines Unternehmens wider – unabhängig von den bilanziellen Gewinnen. Er zeigt, wie viel Spielraum ein Unternehmen für Dividenden, Aktienrückkäufe oder den Schuldenabbau hat. Der FCF ex SBC zieht zusätzlich die aktienbasierte Vergütung ab und zeigt, wie hoch die Cash-Generierung nach Abzug der SBC ausfällt.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher Free Cashflow bedeutet, dass ein Unternehmen echte Finanzkraft besitzt – unabhängig vom bilanzierten Gewinn.
- Er ist oft die solideste Grundlage für nachhaltige Dividenden und Aktienrückkäufe.
- Sinkender FCF kann ein Warnsignal sein – auch wenn der Gewinn stabil aussieht.
📘 Umsatzwachstum
📈 Was ist das?
Das Umsatzwachstum zeigt, wie stark sich die Erlöse eines Unternehmens im Vergleich zum Vorjahr verändert haben – tatsächlich (TTM) und auf Prognosebasis (erwartet).
🧮 Wie wird es berechnet?
Erwartet = (Umsatz erwartet ÷ Umsatz Vorjahr − 1) × 100
Erwartetes Wachstum basiert auf Analystenschätzungen für das laufende Geschäftsjahr.
🏛️ Wofür ist es wichtig?
Ein wachsender Umsatz ist ein zentrales Signal für steigende Nachfrage, Geschäftsausweitung und Marktanteilsgewinne – besonders bei Wachstumsunternehmen.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Wachstum ist der Motor langfristiger Wertsteigerung – besonders bei Technologie- und Wachstumsaktien.
- Wichtig ist nicht nur das aktuelle Wachstum, sondern auch dessen Nachhaltigkeit.
- Prognosen zeigen, ob Analysten weiteres Potenzial erwarten – oder eine Verlangsamung.
📘 EBITDA-Wachstum
📈 Was ist das?
Das EBITDA-Wachstum zeigt, wie stark das operative Ergebnis eines Unternehmens vor Zinsen, Steuern und Abschreibungen im Vergleich zum Vorjahr gestiegen oder gesunken ist.
🧮 Wie wird es berechnet?
Erwartet = (erwartetes EBITDA ÷ EBITDA Vorjahr − 1) × 100
Erwartetes Wachstum basiert auf Analystenschätzungen für das laufende Geschäftsjahr.
🏛️ Wofür ist es wichtig?
Ein steigendes EBITDA ist ein Zeichen für verbesserte operative Ertragskraft – unabhängig von Finanzierungsstruktur oder Abschreibungen.
🎯 Was bedeutet das für Anleger?
- Starkes EBITDA-Wachstum signalisiert operative Effizienz und Skalierung – besonders relevant in Wachstumsphasen.
- EBITDA-Wachstum ist ein Frühindikator für Margen- und Gewinnentwicklung – sollte aber stets im Zusammenhang mit Umsatz und EBIT betrachtet werden.
📘 EBIT Wachstum
📈 Was ist das?
Das EBIT-Wachstum zeigt, wie stark das operative Ergebnis eines Unternehmens (nach Abschreibungen, aber vor Zinsen und Steuern) im Vergleich zum Vorjahr gewachsen ist.
🧮 Wie wird es berechnet?
Erwartet = (erwartetes EBIT ÷ EBIT Vorjahr − 1) × 100
Erwartetes Wachstum basiert auf Analystenschätzungen für das laufende Geschäftsjahr.
🏛️ Wofür ist es wichtig?
Das EBIT-Wachstum ist ein direkter Indikator für die wirtschaftliche Entwicklung des operativen Geschäfts – unter Berücksichtigung der Kapitalintensität (Abschreibungen).
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Steigendes EBIT signalisiert wachsende operative Rentabilität – auch unter Berücksichtigung von Abschreibungen.
- Das EBIT-Wachstum ist ein wichtiges Maß zur Beurteilung von Geschäftsmodellen mit hohen Investitionskosten.
- Im Zusammenspiel mit Umsatz- und EBITDA-Wachstum ergibt sich ein umfassendes Bild zur operativen Entwicklung.
📘 Nettogewinn-Wachstum
📈 Was ist das?
Das Nettogewinn-Wachstum zeigt, wie stark der Jahresüberschuss eines Unternehmens gegenüber dem Vorjahr gestiegen oder gesunken ist – sowohl tatsächlich (TTM) als auch auf Basis von Prognosen (erwartet).
🧮 Wie wird es berechnet?
Erwartet = (erwarteter Nettogewinn ÷ Nettogewinn Vorjahr − 1) × 100
Der erwartete Wert basiert auf Analystenschätzungen für das laufende Geschäftsjahr.
🏛️ Wofür ist es wichtig?
Der Gewinn ist die entscheidende Ergebnisgröße für ein Unternehmen. Ein wachsender Nettogewinn deutet auf steigende Effizienz, stabile Kostenkontrolle und nachhaltige Ertragskraft hin.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Wachsender Nettogewinn stärkt die Bewertung, Dividendenfähigkeit und Kursfantasie.
- Stagnierender oder rückläufiger Gewinn trotz Umsatzwachstum kann auf Margendruck hinweisen.
📘 Free Cashflow-Wachstum
📈 Was ist das?
Das Free-Cashflow-Wachstum zeigt, wie sich der freie Mittelzufluss eines Unternehmens im Vergleich zum Vorjahr verändert hat – also der Betrag, der nach allen operativen Ausgaben und Investitionen übrig bleibt.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Free Cashflow ist der echte, verfügbare Geldzufluss. Wachstum in diesem Bereich ist ein Zeichen für finanzielle Stärke und steigende Flexibilität bei Dividenden, Rückkäufen oder Investitionen.
🎯 Was bedeutet das für Anleger?
- Sinkender Free Cashflow kann auf steigende Investitionen, höhere Kosten oder stagnierende operative Erträge hindeuten.
- Besonders bei Dividendenwerten ist das FCF-Wachstum wichtig – denn Dividenden werden letztlich aus dem verfügbaren Cash gezahlt.
- Ein negativer Trend sollte genauer analysiert werden – er ist nicht zwangsläufig schlecht, aber potenziell ein Warnsignal.
📘 Bruttomarge
📈 Was ist das?
Die Bruttomarge zeigt, wie viel vom Umsatz nach Abzug der direkten Herstellungskosten (Material, Produktion) als Bruttogewinn übrig bleibt – also der „Rohgewinn“ eines Unternehmens.
🧮 Wie wird es berechnet?
Auch: Bruttomarge = Bruttogewinn ÷ Umsatz × 100
🏛️ Wofür ist es wichtig?
Die Bruttomarge gibt Aufschluss über die Profitabilität eines Produkts oder Geschäftsmodells vor Fixkosten, Steuern und Zinsen. Sie zeigt, wie effizient ein Unternehmen produzieren oder einkaufen kann.
🎯 Was bedeutet das für Anleger?
- Eine hohe Bruttomarge deutet auf starke Preissetzungsmacht und effiziente Herstellung hin.
- Sinkende Bruttomargen können auf Kostensteigerungen oder Preisdruck hindeuten.
- Besonders im Vergleich zu Wettbewerbern liefert die Bruttomarge wertvolle Einblicke in die Geschäftsqualität.
📘 EBITDA-Marge
📈 Was ist das?
Die EBITDA-Marge zeigt, wie viel vom Umsatz als operativer Gewinn vor Zinsen, Steuern und Abschreibungen (EBITDA) übrig bleibt. Sie misst die operative Effizienz – ohne Verzerrungen durch Finanzierung oder Buchwerte.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die EBITDA-Marge hilft zu verstehen, wie viel operativer Gewinn ein Unternehmen aus jedem Euro Umsatz erzielt – unabhängig von Kapitalstruktur oder steuerlichem Umfeld.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine hohe EBITDA-Marge zeigt starke operative Ertragskraft – unabhängig von Bilanzierungseffekten.
- Die Marge ermöglicht gute Vergleiche zwischen Unternehmen und Branchen.
- Ein stabiler oder wachsender Wert kann auf effiziente Kostenkontrolle und Skalierbarkeit hindeuten.
📘 EBIT-Marge
📈 Was ist das?
Die EBIT-Marge zeigt, wie viel Prozent des Umsatzes als operativer Gewinn nach Abschreibungen, aber vor Zinsen und Steuern übrig bleiben.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die EBIT-Marge misst die operative Ertragskraft eines Unternehmens unter Berücksichtigung der Kapitalintensität (z. B. Maschinen, Anlagen). Sie eignet sich gut zum Vergleich von Geschäftsmodellen mit unterschiedlich hohen Abschreibungen.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine hohe EBIT-Marge zeigt, dass ein Unternehmen auch nach Abschreibungen effizient arbeitet.
- Sie ist besonders relevant in kapitalintensiven Branchen.
- Langfristig stabile oder steigende Margen sind ein Zeichen wirtschaftlicher Stärke und Preissetzungsmacht.
📘 Nettomarge
📈 Was ist das?
Die Nettomarge zeigt, wie viel vom Umsatz am Ende als „Reingewinn“ übrig bleibt – also nach Abzug aller Kosten, Zinsen, Steuern und Abschreibungen.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Die Nettomarge gibt an, wie effizient ein Unternehmen über alle Stufen hinweg wirtschaftet. Sie zeigt, wie viel Gewinn tatsächlich je Euro Umsatz übrig bleibt.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine hohe Nettomarge zeigt, dass ein Unternehmen nicht nur operativ stark ist, sondern auch seine Finanzierung und Steuerbelastung im Griff hat.
- Vergleiche mit Wettbewerbern geben Einblicke in die wirtschaftliche Qualität.
- Sinkende Nettomargen trotz Umsatzwachstum können ein Warnsignal sein – etwa für steigende Kosten oder sinkende Effizienz.
📘 Free-Cashflow-Marge | ex SBC
📈 Was ist das?
Die Free-Cashflow-Marge zeigt, wie viel Free Cashflow ein Unternehmen im Verhältnis zu seinem Umsatz erwirtschaftet. Der Free Cashflow entspricht vereinfacht dem operativen Cashflow abzüglich der Investitionsausgaben. Die Free-Cashflow-Marge ex SBC berücksichtigt zusätzlich aktienbasierte Vergütungen (Stock-Based Compensation, SBC). SBC verursacht zwar keinen direkten Cash-Abfluss, kann bestehende Aktionäre jedoch durch die Ausgabe zusätzlicher Aktien verwässern. Daher wird SBC bei dieser Kennzahl vom Free Cashflow abgezogen.
🧮 Wie wird es berechnet?
Free-Cashflow-Marge ex SBC = (Free Cashflow − SBC) ÷ Umsatz × 100
🏛️ Wofür ist es wichtig?
Die Free-Cashflow-Marge zeigt, wie effizient ein Unternehmen seinen Umsatz in Free Cashflow umwandelt. Ein hoher Free Cashflow kann dem Unternehmen finanziellen Spielraum für Dividenden, Aktienrückkäufe, Schuldentilgung oder weitere Investitionen geben. Die Variante ex SBC berücksichtigt zusätzlich die wirtschaftliche Belastung durch aktienbasierte Vergütungen und ermöglicht dadurch eine konservativere Betrachtung der Cash-Generierung aus Sicht der Aktionäre.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Eine hohe Free-Cashflow-Marge zeigt, dass ein Unternehmen einen hohen Anteil seines Umsatzes in Free Cashflow umwandelt.
- Das kann dem Unternehmen mehr finanziellen Spielraum für Dividenden, Aktienrückkäufe, Schuldentilgung oder Investitionen geben.
- Die Free-Cashflow-Marge ex SBC berücksichtigt zusätzlich die mögliche Verwässerung durch aktienbasierte Vergütungen.
- Besonders aussagekräftig ist die Entwicklung über mehrere Jahre. Sinkende Werte können beispielsweise auf höhere Investitionen, Veränderungen im Working Capital oder eine schwächere operative Entwicklung zurückzuführen sein.
📘 Ergebnis je Aktie (EPS)
📈 Was ist das?
Das Ergebnis je Aktie (EPS) zeigt, wie viel Gewinn auf eine einzelne Aktie entfällt – und ist eine der wichtigsten Kennzahlen zur Bewertung von Unternehmen.
🧮 Wie wird es berechnet?
Die verwässerte Aktienanzahl berücksichtigt auch potenzielle neue Aktien, etwa durch Optionen, Wandelanleihen oder andere Umtauschrechte.
🏛️ Wofür ist es wichtig?
EPS bildet die Basis für viele Bewertungskennzahlen wie KGV, PEG oder Payout Ratio. Es macht den Gewinn für Aktionäre vergleichbar – unabhängig von der Unternehmensgröße.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- EPS hilft, die Profitabilität pro Aktie zu erfassen – und ist besonders wichtig im Zeitvergleich oder im Vergleich mit Analystenschätzungen.
- Steigendes EPS kann ein Zeichen für stabiles Wachstum oder Aktienrückkäufe sein.
- Wichtig: Verwende verwässertes EPS für realistische Bewertungen – besonders bei stark aktienbasierten Vergütungssystemen.
📘 Free Cashflow je Aktie (FCF je Aktie)
📈 Was ist das?
Der Free Cashflow je Aktie zeigt, wie viel freier Mittelzufluss einem Unternehmen pro Aktie zur Verfügung steht – nach Investitionen, aber vor Dividenden oder Schuldentilgung.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Der FCF je Aktie zeigt, wie viel liquide Mittel pro Aktie tatsächlich im Unternehmen verbleiben – wichtig für Dividenden, Aktienrückkäufe oder Schuldentilgung. Im Gegensatz zum Gewinn ist er schwerer manipulierbar und daher besonders aussagekräftig.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher Free Cashflow je Aktie ist ein Zeichen für hohe finanzielle Flexibilität.
- Er zeigt, wie viel Kapital ein Unternehmen effektiv einsetzen oder ausschütten kann.
- Besonders relevant für dividendenstarke Unternehmen oder solche mit starker Kapitalrendite.
📘 Short Interest
📈 Was ist das?
Short Interest zeigt, wie viele Aktien eines Unternehmens aktuell leerverkauft wurden – also von Investoren geliehen und verkauft, in der Erwartung fallender Kurse.
🧮 Wie wird es berechnet?
Der Wert zeigt den Anteil der Aktien, der aktuell auf fallende Kurse spekuliert wird.
🏛️ Wofür ist es wichtig?
Short Interest dient als Stimmungsindikator: Ein hoher Wert deutet auf Skepsis oder negative Erwartungen gegenüber dem Unternehmen hin – kann aber auch zu einem „Short Squeeze“ führen, wenn der Kurs plötzlich steigt.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein niedriger Short Interest deutet auf Vertrauen in das Unternehmen hin.
- Ein hoher Wert kann ein Warnsignal sein – oder eine Chance, wenn sich die Stimmung dreht.
- Besonders spannend in volatilen Märkten oder vor wichtigen Quartalszahlen.
📘 Employees
📈 Was ist das?
Die Mitarbeiteranzahl zeigt, wie viele Personen ein Unternehmen weltweit beschäftigt – ein Indikator für Größe, Struktur und Geschäftsmodell.
🧮 Wie wird es berechnet?
🏛️ Wofür ist es wichtig?
Sie hilft bei der Einschätzung von Skaleneffekten, Effizienz und Personalkosten. Zusammen mit Umsatz und Gewinn lassen sich Kennzahlen wie Produktivität je Mitarbeiter ableiten.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Viele Mitarbeiter bedeuten große operative Komplexität – aber auch hohes Umsatzpotenzial.
- Produktivität je Mitarbeiter ist ein wichtiger Indikator für Effizienz.
- Besonders spannend bei stark wachsenden Tech- oder Industrieunternehmen.
📘 Umsatz je Mitarbeiter
📈 Was ist das?
Der Umsatz je Mitarbeiter zeigt, wie viel Erlös ein Unternehmen durchschnittlich pro Beschäftigtem erwirtschaftet – eine Kennzahl für Effizienz und Produktivität.
🧮 Wie wird es berechnet?
Die Mitarbeiterzahl stammt in der Regel aus dem letzten verfügbaren Jahresbericht.
🏛️ Wofür ist es wichtig?
Diese Kennzahl hilft, Geschäftsmodelle zu vergleichen – insbesondere zwischen arbeitsintensiven und technologiegetriebenen Unternehmen. Ein hoher Wert deutet auf Automatisierung, Effizienz oder hohen Wertschöpfungsanteil hin.
🧮 Berechnung
🎯 Was bedeutet das für Anleger?
- Ein hoher Umsatz je Mitarbeiter spricht für ein skalierbares und margenstarkes Geschäftsmodell.
- Ein niedriger Wert kann auf arbeitsintensive Prozesse oder geringere Wertschöpfung hinweisen.
- Besonders hilfreich beim Vergleich von Tech- vs. Industrieunternehmen.
Cellectis SA Sponsored ADR Aktie Analyse
Analystenmeinungen
13 Analysten haben eine Cellectis SA Sponsored ADR Prognose abgegeben:
Analystenmeinungen
13 Analysten haben eine Cellectis SA Sponsored ADR Prognose abgegeben:
Cellectis SA Sponsored ADR Events
🇩🇪 Neu: Alle Transkripte jetzt auch auf Deutsch verfügbar!
Abonniere Premium, um Transkripte und KI-Zusammenfassungen auf Deutsch zu lesen.
Vergangene Events
|
NOV
13
Q3 2026 Earnings Call
vor 9 Tagen
|
|
SEP
14
Special Call - Cellectis S.A.
vor 2 Monaten
|
|
MÄR
20
Q4 2025 Earnings Call
vor 8 Monaten
|
aktien.guide Basis
Cellectis SA Sponsored ADR — Q3 2026 Earnings Call
1. Management Discussion
Hello and welcome everyone joining today's Cellectis Third Quarter 2026 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the meeting over to Arthur Stril, Chief Financial Officer and Chief Business Officer. Please go ahead.
Good morning, and welcome everyone to Cellectis's third quarter 2026 business update and financial results conference call. Joining me on the call today are Dr. Andre Choulika, our Chief Executive Officer, and Dr. Adrian Kilcoyne, our Chief Medical Officer.
Yesterday evening, Cellectis issued a Form 6-K and press release reporting on financial statements for the nine-month period ended September 30, 2026, and a business update. Reports and press releases are available on our website at cellectis.com. As a reminder, please note that this presentation contains forward-looking statements within the meaning of applicable securities laws, including statements regarding our strategy, development programs, financial condition, and expected cash runways. These forward-looking statements are based on current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
For a discussion of these risks and uncertainties, please refer to our filings with the U.S. Securities and Exchange Commission and our annual financial report prepared in French. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements contained in this presentation. I would now like to turn the call over to Andre.
Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. Two months ago, we announced a strategic transformation of Cellectis into an in vivo gene editing company. In September, our team has been fully committed to this new chapter.
We're starting with severe dyslipidemia, where the unmet medical need remains high. In severe hypertriglyceridemia, persistently elevated triglyceride levels can expose patients to serious complications, including acute pancreatitis, while in severe hypercholesterolemia, prolonged exposure to very high LDL cholesterol substantially increases the risk of cardiovascular disease. For many of these patients, treatment can mean daily pills or repeated injections over the long term without always achieving sufficient lipid control.
Our approach is different: a single injection designed to deliver a potential long-lasting effect. This is what HEAL-101 and HEAL-201 are being developed to achieve. Let me start with HEAL-101, our in vivo base editing candidate, targeting the APOC3 gene for severe hypertriglyceridemia. At the European Society of Gene and Cell Therapy in October, we presented an extended preclinical dataset.
After a single administration of HEAL-101, up to 70% of APOC3 genes with activity restricted to the liver consistently reduced triglycerides by 76% in a disease model. Taken together, these results strengthen our confidence in HEAL-101 as we continue to advance the program throughout the clinic.
Adrian will walk you through the details in a moment. The initiation of the investigator-initiated trial in China is on track, with preliminary clinical data expected in the second half of 2027.
Turning now to the second lead program, HEAL-201, an in vivo gene editing candidate targeting the PCSK9 gene for severe hypercholesterolemia. It is designed to durably silence PCSK9 without altering the DNA sequence. Our preclinical data are encouraging.
In vitro, in a human hepatic cell line, our PCSK9 epigenetic modulator achieves high on-site epigenetic editing with a mean above 90% and no off-site changes in gene or protein expression detected. In vivo, it reduced plasma PCSK9 levels by more than 90% in a humanized liver mouse model.
Building on these results, we are now preparing the next step, which we plan to be Phase 1, with preliminary clinical data expected in the first half of 2028. Now, I'd like to say a word about our legacy cell therapy programs.
Stopping the development of lasme-cel and eti-cel was not an easy decision. Behind these programs are patients and families, as well as investigators and site teams who have been part of these programs over the years. We're deeply grateful to all of them.
Our priority now is clear, to advance HEAL-101 and HEAL-201 towards the clinic while maintaining the financial discipline required to reach the key milestones ahead. Alongside this strategic focus, our partnership with AstraZeneca, Servier, Allogene, and Iovance remains an important source of value for Cellectis. With that, I hand over to Adrian, our Chief Medical Officer, who will take you through the HEAL-101 data in more detail.
Thank you, Andre. Good morning, everyone. Let me start with a brief reminder of how HEAL-101 works. HEAL-101 is a TALE-based editor designed to make a single C-to-T conversion in the APOC3 gene. This creates a stop codon that prevents production of the APOC3 protein without cutting DNA or creating a double-strand break.
The data we presented at ESGCT built on what we first shared in September and addresses four key questions. one, how efficiently HEAL-101 edits its target? two, how precise that editing is? three, whether it translates into a functional effect; and finally, where that activity occurs. In a human hepatic cell line, HEAL-101 achieved a mean APOC3 editing of approximately 90% while generating minimal indels and no detectable DNA double-strand breaks at the target site.
Additionally, no detectable editing was observed at the top putative off-target sites, and this editing resulted in a marked reduction in APOC3 protein secretion. In a normolipidemic humanized liver mouse model, a single intravenous dose resulted in a mean APOC3 editing of approximately 65%, with editing levels reaching up to 70%. This was accompanied by lower circulating APOC3 levels and lower triglycerides, demonstrating the effect from gene editing to protein reduction and ultimately to the lipid phenotype. Importantly, we observed no significant increase in ALT levels compared to the untreated controls.
In a hypertriglyceridemic human APOC3 transgenic mouse model, which more closely reflects the disease setting, HEAL-101 reduced APOC3 levels by 67%. This translated into a 76% reduction in triglycerides, consistent with the efficacy we first reported in September.
Importantly, editing was detected in the liver with no significant editing detected in the other tissues analyzed. This liver-restricted activity is consistent with the intended profile of our liver-directed LNP delivery approach and is an important consideration as we advance HEAL-101 towards the clinic.
Taken together, these preclinical data show a consistent profile: efficient and precise editing, a functional effect on triglycerides, and editing activity restricted to the target organ. As Andre mentioned, our goal with HEAL-101 is to develop a single administration therapy with the potential to provide a lasting reduction in triglycerides. Initiation of the investigator-initiated trial in China is on track, with preliminary clinical data expected in the second half of 2027.
We look forward to sharing more details on the trial as it progresses. With that, I'll turn the call over to Arthur, our Chief Financial Officer and Chief Business Officer, for our third quarter financial results.
Thank you, Adrian. I will now walk you through our financial results for the third quarter of 2026. As Andre highlighted, this is a transition quarter. As part of our strategic transformation, the exit of lasme-cel and eti-cel clinical programs is proceeding as planned.
Enrollment has stopped, site closeout activities are underway, and treated patients will continue to be monitored in accordance with protocol-specified follow-up requirements.
Furthermore, the realignment of the company's operating model is ongoing. In connection with this initiative, the company currently expects its global headcount to be reduced by up to 70% from its pre-transition level over the course of 2026 and 2027, subject to the completion of the applicable French Works Council consultation process and compliance with applicable French and U.S. labor law requirements.
Going forward, we expect Cellectis cash spending to be primarily focused on advancing our pipeline, including HEAL-101, HEAL-201, and potential new product candidates, as well as funding runoff restructuring costs.
As of September 30, 2026, our cash, cash equivalents, restricted cash, and fixed-term deposits classified as current and non-current financial assets amounted to $149 million, compared to $211 million as of December 31, 2025.
The $62 million change was primarily driven by payments to suppliers of $37.9 million, payroll-related payments, salaries, bonuses, and social charges of $37.5 million, lease payments of $7.3 million, repayments of $4.0 million under the PGE loan, and capital expenditures of $1.9 million, offset by $21.4 million of cash received from customers and $5.4 million of interest received from our financial and cash equivalent instruments.
Consolidated revenues and other income were $19.9 million for the nine-month period ended September 30, 2026, compared to $67.4 million for the nine-month period ended September 30, 2025. The $47.5 million decrease year-over-year was primarily driven by the level of activities performed under the research plans of the AstraZeneca joint research collaboration agreements during the period.
Consolidated R&D expenses were $108.8 million for the nine-month period ended September 30, 2026, compared to $69.1 million for the nine-month period ended September 30, 2025.
The $39.7 million increase was primarily driven by a $34.9 million impact from the strategic transformation announced in September 2026, including a $26.6 million one-off impairment loss, $6.2 million of termination benefits, and $2.1 million of costs related to the closeout of the lasme-cel and eti-cel programs.
Excluding the one-off impacts, research and development expenses increased by $4.8 million in 2026 compared to 2025, primarily driven by a $1.4 million increase in non-cash stock-based compensation expense and a $2.1 million increase in purchases and external expenses, mainly attributable to the higher clinical development costs incurred before the strategic transformation.
Consolidated SG&A expenses were $17.5 million for the nine-month period ended September 30, 2026, compared to $15.0 million for the nine-month period ended September 30, 2025. The $2.5 million increase was primarily driven by a $1.1 million impact of the strategic transformation announced in September 2026, comprising $0.9 million of termination benefits.
Excluding the one-off impact, selling, general, and administrative expenses increased by $1.4 million, mainly due to higher stock-based compensation expense.
Turning to our financial results, the consolidated net gain for the nine-month period ended September 30, 2026, was $5.2 million compared to a net financial loss of $25.6 million for the nine-month period ended September 30, 2025. The $30.8 million difference reflects a $10.8 million increase in financial income and a $20.0 million decrease in financial expenses.
The $10.8 million increase in financial income was primarily attributable to a $14.3 million increase in non-cash gains recognized from fair value measurements, mainly reflecting a gain from the fair value measurements of the tranche A, B, and C warrants issued to the European Investment Bank (EIB) during the period compared with a fair value loss in the same period in 2025, partially offset by a $2.7 million decrease in interest income earned on cash, cash equivalents, and financial assets, and a $1.0 million decrease in foreign exchange gains.
The $20.0 million decrease in financial expenses was primarily attributable to a $23.7 million decrease in foreign exchange losses, mainly resulting from the appreciation of the U.S. dollar against the euro, a $5.9 million decrease in losses from fair value measurements as the tranche A, B, and C warrants issued to the EIB generated a fair value gain over the period, and a $9.7 million increase in other financial expenses, mainly due to the expected credit loss allowance related to a financial warranty.
For details on our consolidated net loss attributable to shareholders for the nine months ended September 30, 2026, I invite you to refer to our press release. As Andre mentioned, once our realignment is fully implemented as planned, we will have a cash runway into the second half of 2028.
Importantly, this is anticipated to take us beyond the expected first clinical data from HEAL-101 in the second half of 2027 and from HEAL-201 in the first half of 2028. Our priorities are clear: execute our strategic transformation with financial discipline and advance HEAL-101 and HEAL-201 towards their key clinical milestones. With that, we welcome your questions.
[Operator Instructions] We'll take our first question from Amin Makarem with Jefferies. Please go ahead.
2. Question Answer
Hi. A couple of questions from us. For HEAL-101, what level of triglyceride lowering would be enough to move into a global development? Does it need to be closer to that roughly 80% reduction we see from plozasiran, or would a 50% to 60% reduction be enough? And then for HEAL-201, what LDL-C reduction did you see alongside the greater than 90% PCSK9 suppression? Yes, this would be helpful if you can address those two.
Thanks for the question, and I'll take the first part of that. So, our anticipation is that the efficacy we will see will be at least as good as the current treatment. So, I think that's our expectation. There is another aspect to it, which I think we like to talk about in that one is the percentage reduction, and the other is the proportion of patients hitting target.
And that's incredibly important. We want to really optimize the number of patients hitting under that target of 500 for a number of reasons. One, the risks associated with hypertriglyceridemia are really based on it being over 500, so that is critical, and certainly in the high-risk patient population and previous acute pancreatitis, once you get under that 500, your risks essentially are eliminated. So that's important to also consider.
We also know that between 200 and 500, when we look at any outcomes, we're not able to see a real benefit. So two aspects: we want to optimize the number of patients who hit below target, but we have no reason to believe based on our current data package that we would be anything other than at least as good as the current therapies available.
And again, with the HEAL-101 program, to remind people that this is being run in China, the regulations in China have changed rather dramatically this year, and this is supported by a very robust preclinical package.
For the PCSK9 90% reduction, we haven't gone public on the LDL-C reductions yet. That will be coming in June, of course, but we'll certainly follow up with you.
[Operator Instructions] We will move next with Jack Allen with Baird. Please go ahead.
Great. Thanks for the questions and congrats to the team on the progress made over the course of the quarter. Two quick ones from our end. I guess the first I wanted to ask on HEAL-101 again. I just wanted to, I guess, poke management's brains a little bit here on how they selected APOC3 versus ANGPTL3.
I know there are gene editors going after both these targets. I'm just curious what drove you towards APOC3 and what attracted you to that target? And then briefly on HEAL-101 and the study startup activities, have you identified the sites you're going to go into in the investigator-led study in China? And then any color you can provide on the dose escalation plans there: do you expect to start at an efficacious dose, or what doses could you escalate through? Thanks so much.
Great, well I can start on that, and I think there's three questions in there. You may have to remind me of some of those as we're going through, Jack. So the first: why APOC3 versus ANGPTL3? Given that our indication was hypertriglyceridemia, the first thing we did is actually extensive market research to see what is required in the marketplace.
Specifically for hypertriglyceridemia, the general feeling based on that extensive market research across cardiologists, endocrinologists, and internists was that optimal reduction in triglycerides was important, and the general feeling was that APOC3, in terms of specifically targeting triglycerides, was still superior to ANGPTL3 in that regard. So it seemed to be the right indication and the right target for specifically hypertriglyceridemia.
In terms of the site in China, yes, we have chosen where we're going to be running this in China. We haven't got agreement to make that public in China, but once we have that, we will share it with you. But suffice to say that we're very satisfied that we will be able to recruit at a pace, given the access to a huge number of patients. The PI in the trial would be considered probably the number 1 treater in this space in China and has done all the other gene therapy-related programs in the past, so extensive experience, and they specifically wanted to do this program because they like the technology; they perceive it to be potentially safer based on no nicks in DNA.
The third question was dose escalation. That's really important to us. Again, in choosing the sites in China, the reason we chose the PI was their desire to yes, start with a safe dose, but also an incredible desire to start with an effective dose. So they have developed their own modeling specifically for these types of treatments that allows them to look at again the very strong preclinical package we have and do extensive modeling to allow essentially a slightly higher starting dose.
So we do still anticipate dose escalation, of course; it is a Phase 1 program. However, we do anticipate the dose at which we start will be effective. Now, it may not achieve the optimal efficacy, but it does lead into what the expectations for data readout are for 2027. So once we start the dose escalation in Q1, that first cohort we anticipate will have a level of efficacy, and we would anticipate then by the end of the year, you will start to see the durability of that effect, which is a unique proposition from Cellectis. And indeed, if we start recruiting patients in Q1, by the end of the year, we should be starting to see the nine-month type of durability of the effect.
One thing I'd like to add, hi Jack, that's Andre, is APOC3 is a way more effective metabolic intervention on the reduction of triglycerides than ANGPTL3, which is effective, but not as effective. And our goal here is not to have a product that lowers triglycerides and LDL, but essentially to try to reduce the incidence of triglycerides to effectively treat the potential risk of pancreatitis.
And we think this is the best-adapted target, and there is a clear proof of concept with ASOs and RNAs on this target that is very valid. So there is a real unmet medical need on this side for a very drastic lowering because of the metabolic action.
[Operator Instructions] Our next question comes from Yanan Zhu with Wells Fargo. Please go ahead.
Great, thanks for taking our questions. On the APOC3 program, could you potentially compare the APOC3 and triglyceride reduction between your base editing approach and a nuclease editing approach? Just wondering whether there could be any potential differences, and then could you discuss the LNP that you are using and your level of confidence in terms of liver safety? Thank you.
Thank you for the question, Yanan. This is Andre. Well, the effectiveness of either making base editing versus cutting DNA with a double-strand break is like the depth of action is very similar, with a slight upside for base editing. The difference essentially is that you need to have like replication inside the cell, but liver cells replicate quite intensively, and therefore you have very effective base editing. We decided to go for in vivo gene editing with base editors and epigenetic modifiers because the risk of snapping DNA and having what's called non-homologous end joining that would induce a mutation in the gene carries a high risk of potentially having a very, very low rate, but still a rate of translocation or chromothripsis or loss of heterozygosity.
It means you can lose potentially an arm of the chromosome or potentially have the chromosome recombine somewhere else, et cetera. To just use the deaminase, this will just switch one base for another, and after this, there's replication. So the efficiency is similar, if not slightly better, with the base editor, but the risk is so much lower, whereas the main reason to use a nuclease or a double-strand break, such as Cas9, would be essentially to do either gene insertions or gene replacements or large portions of deletion.
But if you just want to interrupt the gene, you can either interrupt it through methylation, deacetylation, or essentially base editing inducing either a mutation in the coding sequence or at splice sites.
Thank you, Andre.
I don't know if this answers the question.
Yeah, that's helpful. Thanks, Andre. How about the LNP liver safety?
Yes, it's definitely a safety approach.
Yeah, as I say, we do have NHP data, we have mouse data. Suffice to say, the liver toxicity has been very reassuring.
[Operator Instructions] Our next question comes from Lukas Shumway with Barclays. Please go ahead.
Hi, thanks for taking the question. Real quick on the data reported in the preclinical poster and here today versus September for HEAL-101. Can you talk about what the difference is in the dataset and the disease model there?
Well, yes, actually there are two different types of models that have been used. The first one is essentially a model that is a human liver that has been grafted on a NOD mice, and so you have the human gene, and like of course the mouse gene would not work in this setting, and so you need to really test the compound on a real human gene. And so it has been tested in the liver. The problem is that these mice do not develop sHTG, so they're not sick. They're differently sick, actually. They have like an immune deficiency, but they're not really sick.
So the model that has been used, the second model that has been used, is essentially a model that is a transgenic mouse, so it's a mouse liver, but that has a transgene in multiple copies. I think it's approximately over 50 copies of the human APOC3 gene. And therefore, as there is a lot of APOC3 that is secreted by the mice, the mice develop an sHTG.
Therefore, it allows us to show an effective reduction of triglycerides in these types of models, and you can make a clear correlation and that's what the poster shows between the reduction of APOC3, which goes back to the first question, like the choice of APOC3 versus ANGPTL3. And we see that even over 50 copies in a single hepatocyte can be very efficiently edited by the TALE-based editor and reduce triglycerides.
And there is a clear correlation between the number of edits and also the reduction in like the drop in triglycerides. So that's essentially what has been shown, working between like a human liver and really diseased mice.
Sorry, okay, so what I meant was in that disease model, the overexpression model, what's the difference between the data now and the data in September? Because the numbers are different.
Well, essentially the correlation that you can do between the reduction in triglycerides, like there were more points of measures that have been done and more dose escalation and the way it has been shown.
It's not, of course, drastic, and we should have said that essentially these types of like the work that was presented in September versus the poster is not that much meaningful, but there is like more of a ground of data that has been shown there.
[Operator Instructions] We will move next with Joshua Werman with Citizens. Please go ahead.
Hi, this is Joshua Werman on for Silvan. Thanks for taking my question and congrats on the updates here. Maybe just going back to the LNP briefly: is this a delivery system that has been used clinically before either by Cellectis or elsewhere? And then how can maybe that help us, you know, be informed on the dose escalation?
And then additionally, building off the decision to target maybe APOC3 over ANGPTL3, how are you thinking about the ultimate addressable population for HEAL-101? If the proof of concept is robust, where do you think the biology could support expansion beyond sHTG? Thank you.
Well, first of all, the first question was on the LNP. The LNP, yes. Sorry about that, I was thinking about the second question. So, yes, the answer is yes. So we've been working currently with a biotech company, not a CDMO. We're going to transfer to a CDMO after for working with the LNP but the biotech company has been using these LNPs in the clinic for transduction of liver cells, but not with messenger RNA or RNA, not specially messenger, sorry, with RNA for liver transduction with a very good safety profile, but very high efficiency.
And it's like a next-generation type of charged type of lipids that have been put and nicely decorated too, that gives a very good transduction level in other types of settings in the liver with RNA and that are currently in the clinic.
Therefore, this is why we choose this. And there is a very nice modeling that has been done with animal models such as NHPs and mice that we're currently conducting that would allow us to translate this and arrive when we start in the clinic with probably the best, most optimized type of dose leveling at the time.
So in between now and the time where we'll have the IIT active, then this modeling will be between the human data that has been obtained so far, plus the animal models, NHPs and mice, we'll be able to do a very good dosing with this. But they've been really well proven for lack of toxicity.
The other thing is, because it has been used clinically before, we have the biotech's NHP data, which we've been able to recapitulate, which is very helpful, but also it allows us to go to a dose level, which I think is part of your second question, it allows us to think about a potentially higher starting dose as well, based on the modeling. So it's given us that flexibility, which has been helpful.
And the second part of the question is the size of the market, I think ANGPTL3 versus APOC3, and where could you go beyond? Well, our belief is an APOC3 target is very much a hypertriglyceridemia target, but this market is incredibly large. So if we look at the target population that we're looking at, it's about 1.1 million across the U.S. and EU5 or EU4 plus UK. So this is an incredibly large market for an APOC3 target. Again, we've done a lot of market research to see where this product would fit within that market, and the view is, based on the potential durability of response, this would be a best-in-class product. So we will be launching this into an established market, being best-in-class.
The comparison between ANGPTL3 and APOC3 is that when you're treating severe hypertriglyceridemia, you want a product that is totally focused on this, and you will choose the most efficient one. If you're treating, for example, hypercholesterolemia, which is also active, I think you'll probably use PCSK9.
So I know that this might cover both indications, but as for the reduction, it's like not the highest performer in both, but these are two different types of diseases. And usually the mix between the two, the overlap is quite small. So it's better used for very specialized drug indications.
Yeah, and two other important points when you think about peak sales is we talk about addressable market, but you also have to think about pricing. So if, as we are thinking about these to be long-lasting treatments, and if you look at the pricing per year per patient of other therapies in the sHTG space, I think proving durability in years will allow us to extract a bigger pricing in terms of, you know, the per-year cost of current therapies.
And then finally, when you think about cost of goods, this is LNP mRNA formulated in LNP, which is extremely cheap. So the gross margin potential of these products is absolutely tremendous. So don't only think about the addressable market in terms of the number of patients, but I think these will unlock pricing and cost of goods opportunities.
There's a final thing to add, which was we have looked at the market research in this regard regarding the positioning of an ANGPTL3 target, and the view was this was more a mixed dyslipidemia product. And the number of patients that have overlapping LDL-C with hypertriglyceridemia is relatively small. So they see the ANGPTL3 probably preferentially moving into that hypercholesterolemia mixed dyslipidemia space. They believe that APOC3 is superior in terms of triglyceride lowering.
[Operator Instructions] At this time, there are no further questions in queue. I will now turn the meeting back to Andre Choulika for closing comments.
Well, thank you, everyone, for attending this quarterly financial statement review for Cellectis and update for the quarter. As we said, we keep on the same timing as we said in September, so we're really excited about what's going to happen in '27.
So keep updated on the company on a regular basis, and Cellectis will be present at many conferences if you want to follow up on the discussion. And in the meantime, we'll continue the execution. And I would like to thank you for your time.
This concludes today's conference. Thank you for participating. You may now disconnect.
Transkripte auf Deutsch freischalten
- Alle Event Transkripte auf Deutsch
- Sofortige Übersetzung
- KI-Zusammenfassungen für die wichtigsten Insights
Cellectis SA Sponsored ADR — Special Call - Cellectis S.A.
1. Management Discussion
Good morning, ladies and gentlemen. Welcome to the Cellectis Live conference call, English session. [Operator Instructions]
This call is being recorded on Monday, September 14, 2026. I would now like to turn the conference over to Arthur Stril, CFO and CBO. Please go ahead.
Good morning, everyone, and thank you for joining us. I am Arthur Stril, Cellectis' Chief Financial Officer and Chief Business Officer. Before we begin, please note that this presentation contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, development programs, financial conditions and potential future prospects. These forward-looking statements are based on our current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
For a discussion of these risks and uncertainties, please refer to our filings within the U.S. Securities and Exchange Commission, including, without limitation, our 6-Ks, annual report on Form 20-F, our press releases and annual financial report prepared in French. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements contained in this presentation. Here is our agenda and speakers for today. Dr. Andre Choulika, our Chief Executive Officer; and Dr. Adrian Kilcoyne, our Chief Medical Officer. We will walk you through Cellectis, a Gene Editing Company, our in vivo gene editing pipeline, followed by our strategic transformation. We'll then present our next steps and open the floor for your Q&A.
I would now like to turn the call over to Andre.
Thank you, Arthur. Good morning, everyone, and thank you for being here. I'm Andre Choulika, Co-Founder and CEO of Cellectis. I want to share with you today is one of the most important updates in the history of this company, a deliberate science-driven turn towards the next chapter of Gene editing. I'll walk you through where we come from, where we're going and why we believe this is the right moment to make this move. Let me start with a simple idea, the one that has defined this company for a quarter century, Gene Editing. Cellectis was founded more than 25 years ago as a pioneer in this field. Long before Gene Editing became a household term, it is today.
And our conviction has never wavered -- gene editing is not an incremental improvement in medicine. It's a paradigm shift. At its core, gene editing does one thing. It intervenes at the level of the genome to change how a gene behaves. You can do that in 3 ways. You can silence a gene, you can activate a gene or you can repair a gene.
Keep those 3 verbs in mind, silence, activate, repair. This is what it's going to be all about. Why does this matter so much? Because genetics drives diseases, cancer, diabetes, obesity, neurological disorder, immune conditions, even the biology of aging. At the root, these are genetic variations in the genome, aberrant gene expression, polymorphism, gene doing too much or too little. The logic of gene editing is simple, fix the gene and you fix the disease. Now there are two ways to do that. EX VIVO, where we collect patient cells, edit them under controlled manufacturing conditions and infuse them back.
That's the world of CAR-Ts, and it's the world where Cellectis built its leadership. And IN VIVO, where we deliver the editor directly into the body to the target tissue and do the editing inside the patient. This is the pivot in one sentence. We're building on our EX VIVO leadership to advance the next frontier in IN VIVO gene editing. Same expertise, same molecular toolbox delivered in a fundamentally simpler way. But let's talk about in vivo gene editing and why I'm so excited about it. The liver is the chemistry lab of the human body. And conveniently, it's also the easiest address for a lipid nanoparticle to find.
Everything you inject intravenously ends up passing through it. The concept is simple. A single intravenous injection, product travels to the liver, editor does it work inside the liver cells and the effect is designed to last. No apheresis, no manufacturing per patient, no hospitalization for cell collection and preconditioning, one injection for a long-lasting effect. And what exactly is the product? It's remarkably simple. It's a messenger RNA that encodes a gene editor, all base editor. -- packaged inside lipid nanoparticle an LNP. It's a well-established, well-understood delivery technology. The messenger RNA is transiently expressed, it does a job and disappears, but the edit it makes in the genome is permanent.
That's the elegance, onetime treatment, lasting effect, which brings me to the heart of today's news. We've made the decision to advance 2 preclinical candidates, both in dyslipidemia, diseases of blood lipids where the genetic drivers are exceptionally well understood. The first is HEAL-101, targeting the APOC3 gene in severe hypertriglyceridemia. The second is HEAL-201 targeting PCSK9 in severe hypercholesterolemia. Both are messenger RNA plus LNP products. Both go after targets that are exceptionally well validated by other modalities and both are designed around the same promise, a single IV injection with a potentially long-lasting effect. HEAL-101, this is gene surgery for severe hypertriglyceridemia. Severe hypertriglyceridemia doesn't get the headlines of cardiovascular diseases, but it should. These patients live with the risk of acute pancreatitis, a condition that hospitalizes you, is extremely painful and can kill you. They carry elevated cardiovascular risk. The quality of life is poor and their options are thin. 1 million to 2 million high-risk patients across the U.S. and Europe, not a rare disease, but a neglected one as APOC3 is a very small protein hard to address with the drug.
Here's the program we've built for them. Here's HEAL-101 in a single frame. Severe hypertriglyceridemia at the high risk of pancreatitis. The target is APOC3. APOC3 has been validated twice over by other modalities. The technology is a TALE-Base Editor that disables the gene. The goal is to make a single treatment with a durable triglyceride lowering. We have already obtained preclinical data strong enough that we're heading to the clinic. Now let me explain how it works because the mechanism is where our differentiation really shows.
HEAL-101 is a base editor -- rather than cutting the DNA, which is how first-generation gene editing works, it changes a single letter in the genetic code, a precise conversion of one base, the C to a T, at exactly the position we choose in the APOC3 gene. And this is the key point for safety. There is no DNA break. We're not relying on the cell to repair cut. We simply rewrite one letter. No double-strand break means the potential for cleaner, improved safety profile that matters enormously when you're treating patients in vivo. What does changing one letter accomplishes? It creates a stop codon, a stop signal inside the gene.
When the cell reads the gene, it now stops early. The full APOC3 protein is never made. In plain term, we introduced one tiny precise edit and the gene that drives the disease is switched off. This is gene surgery. And here's the evidence. When we introduce HEAL-101 into human liver cells, we see highly efficient editing right at the target site in the left panel. Just as important, look at the right panel across the top putative off-target sites, we see essentially no modification -- high on-target activity, high specificity. This is exactly the profile you want to see before moving into humans. The functional consequence follows directly.
As we increase the dose of HEAL-101, we see the frequency of disabling edit climb. And in parallel, the secretion of APOC3 falls. Editing goes up, disease-driving protein goes down. The biology behaves exactly as designed. Then we move into humanized animal models, mice engineered with human liver cells, and we see the full chain of cause and effects in the living organism, precise editing of APOC3, a clear decrease in the APOC3 protein and the outcome that matters clinically, a real drop in triglycerides. And the magnitude of that effect is what you -- I want you to remember today. In affected mice, a single administration of HEAL-101 produced at a 70% -- produces a 70% reduction of APOC3 and a 76% reduction in triglycerides, 76% from one treatment.
This is the kind of effect that can change a disease, not just manage it. Now to our second program, HEAL-201, a slightly different, equally powerful type of gene surgery. The disease is severe hypercholesterolemia, high LDL cholesterol or the so-called bad cholesterol. LDL is the leading driver for atherosclerotic cardiovascular disease, and we know that lowering it reduces cardiovascular events, yet a large number of patients simply cannot get to goal. Even on maximum tolerated therapies, we focused on the highest need patients, younger, high-risk individuals who had a premature cardiovascular event and still have persistently elevated LDL despite everything available today. Again, roughly 1 million to 2 million patients across the U.S. and Europe. Here's HEAL-201 at a glance. The indication is severe hypercholesterolemia, the target, the PCSK9 gene, one of the most thoroughly validated targets in all cardiovascular medicine. The editing technology is different from the one I just showed. It's a TALE-Modulator that silence PCSK9. I'll come back to the silencing point later. The goal is onetime treatment for durable LDL lowering to reduce cardiovascular risk. And again, we've obtained promising clinical -- preclinical data supporting moving this product candidate into the clinic.
And here's what I want to highlight the breadth of our platform. HEAL-201 works differently from HEAL-101. It's not the base editor. It's an epigenetic modulator. It doesn't change a single letter of DNA at all. Instead, it binds the DNA the gene and silence it epigenetically, turning the gene off while leaving the DNA sequence completely intact. Think of it this way. With HEAL-101, we edit a letter in the DNA. With HEAL 201, we simply flip the switch to off without touching the text, same company, same TALE backbone, 2 entirely different type of mechanism. That's what a real gene editing platform look like. And no DNA sequence change means, again, an additional safety rationale.
The data backs it up with an epigenetic change alone, no sequence modification, we shut down PCSK9 transcription completely. The messenger RNA of PCSK9 dropped to near 0. The gene is effectively turned off at the source. And that translates to the protein. Over the days following treatment, PCSK9 protein secretion falls dramatically and stays down. The target protein is turned off, which is precisely what drives LDL cholesterol lower. Specificity is, of course, critical. So we looked across the entire Transcriptome -- every gene expressed in the cell. The result, PCSK9 is knocked down cleanly while the rest of the genome is essentially untouched in the expression.
Gene surgery uses a scalpel, not a hammer, high specificity for PCSK9 and PCSK9 alone. And crucially, the effect is durable. This is the question everyone asks about epigenetic approaches. Does it hold? In biology, epigenetic pattern is stable over time, even over lifetime. Our data show a rapid and sustained decrease of PCSK9 that remains stable over time, rapid onset with a lasting effect. This is exactly the profile a onetime therapy needs. So -- when you will see the data, let me give you some time lines. And I would like to turn the call over to Adrian to walk you through our clinical plan for HEAL-101 and HEAL-201. Adrian?
Thank you, Andre. I will now outline our development pathway, which is composed of 2 parts. Initially, we have an accelerated path to first-in-human data through an investigator-initiated trial in China. This IIT is being run under the new regulations, which came into effect in May this year, requiring a comprehensive preclinical package. This first-in-human study in severe hypertriglyceridemia is focused on safety, tolerability and establishing that HEAL-101 will lower triglycerides, which we have seen in the compelling preclinical data, some of which has already been shared today by Andre.
It is important to highlight that parallel IND and CTA preparation is ongoing to allow for a seamless transition from -- to the global Phase Ib/II by end of 2027 in the target patient population. This will also inform the path to Phase III. It is important to also recognize that the endpoint of lowering triglycerides is well established as a surrogate endpoint for reduction in the risk of acute pancreatitis. There will be no requirement for a cardiovascular outcome trial for either approval or reimbursement. This has a significant impact on the path to revenues compared with many lipid programs. I will now show the plan for HEAL-201. This plan follows the same strategic pathway as HEAL-101. That is accelerated path to first-in-human data and seamless transition to global Phase Ib/II trials.
This Phase I first-in-human study in severe hypercholesterolemia aims to establish safety and LDL-C lowering, followed by a Phase Ib/II, which will focus on the highest risk population who would benefit most from a single-dose gene therapy offering durable long-term lowering of cardiovascular risk. These include younger high-risk patients, patients with severe genetic hypercholesterolemia, patients with premature cardiovascular disease and patients with persistent elevated LDL-C despite maximal therapy. It is important to highlight that LDL-C lowering is an established and validated surrogate endpoint that is accepted to support approval by both FDA and EMA, which, like HEAL-101, will enable an efficient path to market.
Overall, we believe we have designed clinical programs that offer an accelerated path to first-in-human data that will demonstrate the potential of a single-dose gene therapy to offer long-lasting efficacies in areas of high unmet need. Our anticipated time lines are outlined on the slide now being shown. For HEAL-101, we expect the first patient to be treated in Q1 2027 with data readouts in the second half of 2027. It is important to highlight that early patients may demonstrate the expected durable responses by end of year, which could distinguish this as a product with best-in-class potential. As stated earlier, HEAL-201 follows the same strategic pathway.
We, therefore, anticipate that first patients will be enrolled in the second quarter of 2027. The first data readout is expected in the first half of 2028, with again, early patients having the opportunity to demonstrate durable responses. In parallel, we continue to accelerate all activities, including IND and CTA-enabling activities with early engagement with the FDA and EMA. Our goal is also to ensure manufacturing is ready to support the demands of global supply. In summary, we have 2 first-in-human-ready clinical programs with preliminary clinical data expected in the second half of 2027 and the first half of 2028, respectively.
Each offers the potential to be best-in-class products with long-lasting efficacy in areas of significant unmet need. I would now like to turn the call over to Andre to present our world-class gene editing capabilities.
Thank you very much, Adrian. Now let me step back up to the platform because these 2 programs are just the first expression of something bigger. This is what sets us apart. Most gene editing companies do 1 or 2 things. We have the full toolbox. With our TALE technology, we can act as a Nuclease, as a Base Editor, as an Epigenetic modulator and as a Transcriptional regulator. TIL-101 uses the base editors. TIL-201 uses the epigenetic modulator and the same core competency span across all columns. Let me make these advantages explicit because it is central. First, a broad toolbox, nuclease gene editing, base editing, epigenetic editing and transcriptional regulation, any modality from one single platform. Second, strong differentiation at the molecular level. Our TALE editors bind DNA without nicking it. with precision down to the base pair and a 32 base pair recognition site that gives us an exceptional specificity.
And third, we can combine these tools for the same indication, any modality, any hybrid combinations of them for safety, to finesse the biology of each diseases. This is a meaningful competitive advantage. So let's talk directly about the pivot, the strategic decision itself and the discipline behind it.
The heat pump landscape have changed and has changed for good reasons. In B-ALL frontline blinatumomab consolidation has cut relapse rates from roughly half to 15% to 25%. In NHL, Cema-cel in frontline consolidation is driving deeper MRD conversions. Bispecifics and ADCs are crowding second line and third line. And there is now an in vivo CAR-T rush in LBCL. In other words, patients are doing better earlier. That is unambiguously good news for medicine. It is also a smaller and more crowded pond for third-line plus therapies. But it changes the math for us. When relapses fall and competition rise, our enrollment slows, trial gets longer and more expensive and the registration moves further into a more crowded market.
Put plainly, the opportunity for Lasme-cel and Eti-cel has narrowed. We looked at this landscape honestly and asked ourselves where Cellectis can create the most value. The answer was clear. So here's the pivot laid out plainly. Cellectis today has Lasme-cel in Phase II and Eti-cel in Phase I. We are making the disciplined decision to exit the internal cell therapy program while continuing to support our existing partners program, which remains valuable. And Cellectis tomorrow is an IN VIVO gene editing company advancing HEAL-101 and HEAL-201 towards the clinic backed by our partnerships. This decision also extends our cash runway into the fourth quarter 2027 into the second half of 2028. We are concentrating our resources where the science, the medical need and the value creation are the strongest. We're making 4 commitments. We accelerate our 2 lead IN VIVO gene editing assets with readouts, HEAL-101 with the first human readout in H2 '27 and HEAL-201 with the first human readout in H1 '28. We exit internal cell therapy development of Lasme-cel and Eti-cel. We continue our existing partnerships, AstraZeneca, Servier and Allogene and Iovance that the value doesn't go away.
We realigned our organization around IN VIVO gene editing and extend the cash runway into the second half of '28. That's IN VIVO gene editing focused company with a full year of financing past its first human readout. Which brings me to where we are heading and to a world you've seen through today, HEAL. HEAL is more than a program. It's our purpose. Gene surgery is editing life for the better. We're not leaving our history behind. We're fulfilling it. With IN VIVO gene editing, we have the immense opportunity to transform medicine at its source and make a paradigm shift in the way patients are treated, a reality.
And I hope you'll be part of this next chapter with us. With that, let me thank you for your attention and open it up. Arthur, David and Adrian are all here so we can read -- can be ready to answer your questions. Thank you very much for your time.
[Operator Instructions]
Your first question comes from Amin Makarem from Jefferies.
2. Question Answer
This is James on for Amin. Congratulations on the strategic transformation. For HEAL-101, what would the program need to demonstrate to be meaningfully differentiated from existing APOC3 directed therapies, including antisense and siRNA approaches? And also just another quick follow-up. For both 101 and 201 programs, what off-target biodistribution work, liver safety work has to be completed for each program? And what remains before the first patients could be dosed?
Well, thank you very much, Amin, for these questions. And I'd like to turn the first question to Adrian and the second part of your question probably to David for all the preclinical work and before getting into the clinic. Adrian?
Yes. Thanks, Amin, for the question. As you've seen from the preclinical data, we get very strong efficacy. So we would expect our efficacy is at least as good as existing therapies. The really important differentiator for us is really based on the gene editing that is safe, but also very durable. We think one of the challenges is we've done market research on this. We've talked to many cardiologists, endocrinologists, et cetera, those involved in treating these patients. And they have identified a group of patients that they will feel would benefit significantly from a very durable patients. Now we've outlined those in the slides, which are those younger patients. But it's really that durability of response. And of course, the level of durability remains to be seen, but there's every anticipation that this will be a very long-lasting effect. And for young patients with significant cardiovascular risk or indeed patients with severe hypertriglyceridemia who run the risk of developing acute pancreatitis, the ability to not have to have repeated treatments for the rest of their lives is very attractive to clinicians and to patients.
So I think really, the importance is the safety of our Gene Editing Technology and the potential for very significant durability of effect. In terms of the off-target, I'll hand over to you, David.
One of the things I would like to add to your question, Amin, here is, well, ASO, RNAi, et cetera, these are not long-term therapies. They can be lasting for a certain period of time. But the problem with most of these diseases is adherence of the patient to the treatment. And that's where the problem comes from. When you have no real symptoms and you have like to take pills on a daily basis, even on a weekly or monthly or sometimes like on 3 months basis, it is complicated for certain patients, especially when they're young, especially when they have like no symptoms, et cetera. Gene surgery is like the surgery concept. People prefer to have like one definitive action in order to fix a problem instead of continuing to go after the symptoms. And I think that this is something that where the medicine of 21st century is going to head at in the coming years and intervention on the genome is going to become one of the big changes where people will stop taking pills as, for example, normal surgery have changed the lives of a lot of patients in terms of certain type of treatments also. David, I would like to turn off like the floor for you.
So as for assessing off-target, we do that at 2 different levels. We assess the off-target at the molecular level for the TALE-Base Editor and TALE epigenetic modifier. And these are pursued essentially in a way that is quite similar to what we've made public for the TALE with a systematic unbiased approach. So we know where the strike will take place, and we're pretty sure that it does only what it's supposed to do. The off-tissue approach is essentially assessed through biodistribution studies made in animal models. And we actually pursue not only the detection of the lipid nanoparticle itself, the lipids, but also the payload and any effect thereof.
So there's essentially a succession of models that have been classically used in the field, and we are going to pursue the same -- and we're pursuing the same path.
Your next question comes from Jack Allen from Baird.
Congratulations on the updates. I guess 2 quick ones from our end. The first is around the proof-of-concept data that we're going to get as early as the second half of next year from HEAL-101. How do you think about dose escalation here and what kind of dose you could potentially enter the clinic? Do you expect the initial doses to be effective doses? And what kind of proof-of-concept data could we expect as it relates to breadth and depth of that data set in the first half of -- or second half of next year? And then I have a quick follow-up as well on the delivery mechanism.
Great question. Maybe Adrian can -- like we've worked a lot on the dose, and I know that you've done tons of work with the physicians. So Adrian, please go ahead.
Yes. Indeed, it's a great question, Jack. Thanks for asking it. It's really important to us that we start at an effective dose. Now I think our preclinical work has demonstrated very reassuring safety and tolerability. So the group we're working with has done extensive modeling to enable us to start at a higher but safe and effective dose. So when we talk about dose escalation, we anticipate we're already starting at a relatively effective dose. So we would anticipate that the initial emerging data will also be giving us some strong safety signals.
Yes, we may have to dose escalate, but it will be far probably less than we might have anticipated. So I think this extensive modeling with a center that has extensive experience in these type of therapies is allowing us to have that higher starting dose.
Got it. And do you have any context around what that dose might be as it relates to milligrams per kilogram? And then just very briefly on the LNP as well, where are you sourcing your LNP from? And is it a novel LNP? Or has it been put in man before? I'm just curious if there's anything to read into as it relates to the safety of that LNP aspect of the delivery here.
For the first part of -- I'll take the first part in terms of the starting dose, and I'll then hand over to David, who can take the second part. In terms of starting, we're not sharing our starting dose for some obvious reasons. But in due course, that will come out. So we'll share that later following the emergence of the first clinical data. But David, you can talk about the LNP in a bit more detail.
Thank you, Adrian. So we are using the latest generation lipid nanoparticle technology with the latest generation ionizable lipid. So the technology we've been using has been validated already in different context and has been optimized for the very targeting that we're pursuing, i.e., the liver with a dose range, which is commensurate with the needs that we've identified and that Adrian just referred to.
Yes.
Just briefly to poke a little bit more on that. As it relates to the validation, I believe, has the LNP been in man and as their clinical experience? Or is it preclinical data that you're referring to there?
So both, but what we're essentially relying on is recent preclinical experience. Clinical experience is ongoing as well, but it's not pursued by us. So it's really essentially validated in models in primates and in other models.
Your next question comes from Lukas Shumway from Barclays...
A couple for me. Have you engaged with FDA at all already to see what the -- what kind of data they are going to want to see in order to bring this into trials in the U.S. And for HEAL-101, have you done any fate mapping for what the protein -- the truncated protein does within the cell? Because like the stop codon that you're introducing is still quite a bit into the protein. So you're still going to get some translation there.
Adrian, do you want to start for like the U.S. deployment?
Yes, absolutely. So as we said earlier, we're doing this as very much parallel activity. So these are ongoing. These are all in plan. So we would anticipate interactions with the regulatory authorities in the coming months. So based on our current interactions, we would anticipate to be in U.S. clinical trials by the end of 2027. Of course, that's all pending the emerging data.
But that is currently aligned and there's nothing that we've seen thus far that would kind of contradict that. But perhaps the second part would be better for David, if you think, Andre?
Yes. Well, for like the truncated protein, thank you very much for your question. And like for the truncated protein, as it's not detectable, by the way, we believe that the protein truncated is not secreted normally and is degradated inside the cell after translation. Most of the time proteins that are misfolded in general go into a cycle of degradation and are eliminated quite rapidly. So there's no residual protein that is a truncated protein that flows around.
Maybe just an element to add in the preclinical models, we have used humanized models with the human protein, and we actually replicated the effect that you saw where after the base editing, there was no more functional protein.
Your next question comes from Salveen Richter from Goldman Sachs.
This is Mark on for Salveen. A couple from us. So on the preclinical data you've shown is the level of editing, I believe, it was like 55% for HEAL-101 in mice and 90% for HEAL-201 in cell lines. Is that approximately what's needed based on competitor data for clinical efficacy in humans and sort of what gives you confidence in the translation? And also on the catalyst path beyond the first-in-human data that we could see next year and in '28, could we see any additional preclinical data maybe in NHPs? I saw on one of the slides you showed in vivo POC data for HEAL-101 in 2026. Just curious what that was and if you could frame expectations here.
Adrian, do you want to get started with the first part of the question?
Yes. As we stated earlier, we believe the level of editing that we're seeing in our preclinical molecules would be broadly comparable to what we've seen in other programs. So therefore, we believe that, that's certainly an acceptable level of editing in order to translate very positively into the human -- first-in-human data. So we believe, again, based on what we've seen preclinically that we'll be at least as good as the existing therapies.
And on the preclinical work, like the question is we are conducting a pretty sizable package of preclinical work actually but done with the clinical center where we're going to start the trial and with a series of companies that are helping us on this will come with like additional rodents data and, of course, NHP data. And -- but that would be concomitant to the start of the IIT and then potentially, we'll see how we communicate on the data. But we are definitely doing a meaningful size of package and like IITs now require IND type of preclinical package, and we're not skipping this.
Your next question comes from Silvan Tuerkcan from Citizens Bank.
Congrats on the update. I have a question, given AstraZeneca is also a partner and which I thought the partnership was focused very much on the CAR-T side of things and also a very large shareholder. Can you just tell us if you've discussed these plans with AstraZeneca, what the future of this partnership look like? Can you say anything else about these other programs you have ongoing with them? Yes, any color on how you view that partnership evolve in the future?
Silvan, thank you very much for the question. Well, of course, AstraZeneca has been very much involved in the discussions, with this turn. And definitely, the partnership will be unchanged. They are very much keen to follow up on allogeneic CAR-Ts. And it's like piece of the agreement, by the way. So as I said, there is like a piece that is like allogeneic CAR-T cells, genetic modification for other type of like cell therapies, which is very strong implication on AstraZeneca side. We would have personally also pursued on the side, but we have limited resources and had to make an arbitration. We're very much strongly believe in the potential of allogeneic cells. It's essentially a question of competitive landscape that we're facing here,
but the allogeneic CAR-Ts and the next generation that we're building up with AstraZeneca is something that is absolutely exciting and mind-blowing, by the way. And we are preserving all the structure inside Cellectis for the execution of this agreement. Same thing for Allogene, unchanged and same thing for Iovance unchanged. So really pushing forward to have all our partnership as successful as possible and keeping all the resources untouched. I don't know Arthur, if you want to add or build up on this. Thanks, Silvan.
Yes, absolutely. I think this is very critical, as you said, Andre, that all our partnerships are continuing in full force and effect. AstraZeneca is a strategic partner. And as we had disclosed at the time, the partnership covers oncology, immunology and rare diseases. So this is definitely a very important partner for us to be accelerating on the platform, and we will keep the execution and the infrastructure around the partnership. So that's absolutely critical to us.
Great. And Eti-cel Lasme-cel, how should we view here the probability of being able to monetize anything here with -- compared to this being a write-off? Like what's just your top-level view on these programs?
Well, Silvan, we started business development initiatives since a certain period of time. We think that there's a lot of interest around these assets, like the fact that the market is diminishing is just that Cellectis is not able finance it given the time lines that we have and the limited cash resources that we have. But there are interest. This is a process -- the business development process is ongoing, and we'll see where it gets at. But it is something that we cannot continue on our side due to our cash constraints.
Your next question comes from Chiara Montironi from Kempen.
I'm here to cover Sebastiaan, and congratulations on the update. So I would be curious to know whether you're also looking at combination strategies for these 2 assets specifically, perhaps in the future or with other assets in the future? And then maybe also a follow-up on Lasme-cel and Eti-cel. Are you -- or do you have any internal time lines in mind to monetize the program and partner it out?
Thank you so much for the questions. And Well, it's a great question. And it definitely goes to like the breadth of the platform of Cellectis and combinations is part of the strategy of Cellectis. The fact that you combine -- can combine base editors with epigenetic modifiers or, for example, transcription activators, et cetera, is a very powerful position we have currently. And considering the fact of having, for example, your question was related to the combo of an APOC3 with PCSK9, the breadth of dyslipidemia across the board is so large that there is a niche for any kind of combination in the field of dyslipidemia.
And each niche is hundreds of thousands, if not millions of patients. And it always makes sense and it can be very differentiated. So the idea that we have and will come back like updating the markets on the future development that we're doing in the field of generating new type of editors in dyslipidemia in general because there's like other potential targets is the ability to tune up certain pathways and the biology of dyslipidemia to get the patient in a situation where the patient gets out of its disease and is, as we say, healed of his disease at the end.
This is the concept we have. So yes, there is a potential for a combo between a base editor and epigenetic modifier without increasing any risk of translocation or anything like this. It's not snapping 2x the DNA. And the second idea is combining PCSK9 with APOC3 can make sense and make sense in certain type of indications with limited number of patients, but still a very large and broad population. So these are the things. First, you have to test the 2 components independently and then the combination could start. And you will see more and more of this like concept developing, and we believe that having all the component of gene editing platform, a very strong competitive advantage of Cellectis platform this approach of combo.
On the second side, the likelihood of having a potential partner on our current cell therapy assets, I think it's like 50-50. It's difficult to say because you never know when you sign something up to the time you signed it. So we're working hard on this. And I think that we'll probably update if there is a transaction that comes up. But we've seen in the past, like before this announcement, meaningful amount of interest on these 2 assets. And the fact that these assets give very strong data in patients, have no safety issues so far.
It's like these assets essentially are in a position where they're not challenged on the medical side. On the contrary, there's a medical need, but this medical need is what's not the same as it was at the beginning of the year, and this might fit potentially some portfolio of certain pharma companies that we would be happy to -- we're currently interacting with. But we'll update you in the meantime. I don't know, Arthur, if you want to add more because you're at the forefront of business development.
Yes. Thanks, Andre. We -- as you said, we are definitely having conversations with different breadth of pharma ranging from large pharma that are active in CAR-T to more midsized pharma to which this could represent bolt-on opportunities. As usual, with BD, it's always very hard to give a time line, but we will definitely pursue this conversation and strive to find the best home for these assets while we focus internally on our IN VIVO gene editing perspectives.
As of the moment, there are no further questions at this time. I'll turn the call back over to Andre.
Well, thank you, everyone. It was great having you all asking all these questions. We're really excited by this next chapter for Cellectis. We believe that we're finally entering what real gene editing means. It means like healing people for diverse type of polymorphis, and we're really excited by this next chapter, and we'll show you, I hope, that this was something that Cellectis needed to do. Thank you very much, and have a great day.
Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.
Transkripte auf Deutsch freischalten
- Alle Event Transkripte auf Deutsch
- Sofortige Übersetzung
- KI-Zusammenfassungen für die wichtigsten Insights
Cellectis SA Sponsored ADR — Special Call - Cellectis S.A.
Cellectis SA Sponsored ADR — Q4 2025 Earnings Call
1. Management Discussion
Hello, and welcome, everyone, to today's Cellectis' Full Year 2025 Earnings Conference Call. [Operator Instructions] Please note this call is being recorded [Operator Instructions]. It is now my pleasure to turn the meeting over to Arthur Stril, Chief Financial Officer and Chief Business Officer. Please go ahead.
Good morning, and welcome, everyone, to Cellectis Fourth Quarter and Full Year 2025 Business Update and Financial Results Conference Call. Joining me on the call today are Dr. Andre Choulika, our Chief Executive Officer; and Dr. Adrian Kilcoyne, our Chief Medical Officer. Yesterday evening, Cellectis issued a 20-F and press release reporting our financial statements for the 12-month period ended December 31, 2025, and a business update. The report and press release are available on our website at cellectis.com.
As a reminder, we will make statements regarding Cellectis' financial outlook, including the sufficiency of cash to fund operations in addition to its manufacturing, regulatory and product development status as well as product development status of its license partners. These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the Securities and Exchange Commission, SEC, and the financial report, including the management report for the year ended on December 31, 2025, and subsequent filings Cellectis makes with the SEC from time to time. I would now like to turn the call over to Andre.
Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. Cellectis was founded with the conviction that gene editing could fundamentally transform how we treat patients in the 21st century. That foundation and ID, we pioneered the allogeneic CAR T approach ready on day 1, built for all patients regardless of their condition. Today, I'm proud to say that Cellectis is the one of the only company running a pivotal Phase II allogeneic CAR T trial, specifically in B-cell acute lymphoblastic leukemia. The past several years have been among the most challenging in recent memory of biotechnology companies. Many programs were shelved and many companies were forced to retreat. While others were stepped back, Cellectis stepped forward. We held the line. We manage our cash with rigor.
We invested where it matters, and we kept our team focused entirely on one thing, delivering clinical results for patients who are running out of time with no therapeutic solution. In 2025, that discipline paid off. In October, at our R&D Day, we presented the full Phase I data set for lasme-cel, our allogeneic CAR T candidate targeting CD22 in relapsed or refractory B-cell acute lymphoblastic leukemia. lasme-cel achieved 100% overall response rate in the target Phase II population. Critically, lasme-cel converted all patients in the target population to transplant eligible candidates. These results were achieved in patients in third line and beyond. Most of them have already failed CD19 CAR T, blinatumomab and inotuzumab. Their options were exhausted.
This is clinical proof that allogeneic CAR T can deliver deep, durable responses in one of the most difficult cancer to treat. Let me take a moment to explain why our bridge to transplant strategy is medically powerful. For patients with relapsed or refractory BLL, only known path to long-term cure is a bone marrow stem cell transplant. But to be eligible for transplant in a patient, a patient must first achieve deep remission, ideally minimal residual disease negative or MRD negative. The challenge is that heavily pretreated patients often too burdened with disease or too time constrained to wait for an autologous therapy to be manufactured. Window is narrow.
This is precisely where our allogeneic CAR T product, lasme-cel becomes a game changer, off the shelf, immediately available. Lasme-cel has the potential to reach a patient in days, not weeks, rapidly eliminate residual disease and open the door to transplant. For the patients, it is the difference between a chance to cure and no chance at all. Without our pivotal Phase II trial now initiated, we will continue site openings in North America and Europe and enroll expansion in 2026. The first interim analysis of the pivotal Phase II trial is expected Q4 2026.
Turning to our second product candidate, eti-cel for patients with relapsed or refractory non-Hodgkin lymphoma. Eti-cel is a best-in-class allogeneic dual CAR T targeting CD20 and CD22 simultaneously, 2 differentiated antigens validated in oncology. This dual targeting is a deliberate answer to one of the most stubborn clinical problem in lymphoma, antigen escape. When cancer cells lose on surface marker to evade a single target therapy, they cannot hide from both. Eti-cel was built for that challenge. At the ASH 2025 Annual Meeting in December 2025, Cellectis presented Phase I interim results, which demonstrated an encouraging overall response rate of 88% and a complete response of 63% in heavily pretreated patients.
These preliminary data underscore the potential of this innovative approach to transform outcomes for relapsed or refractory non-Hodgkin lymphoma patients. Trial is now investigating any potential impact of low-dose interleukin-2 support to significantly enhance expansion and the persistence of CAR T cells to boost CAR T efficacy without exacerbating toxicity. Cellectis expects to present the full Phase I data set of eti-cel this year. Now a few words on our partners. Cellectis is not operating in isolation. Our gene editing platform has become technological backbone of a broader allogeneic CAR T ecosystem.
Two of our key partners are approaching pivotal moment. Servier through Allogene's cema-cel program is currently in a pivotal Phase II study, evaluating it as a consolidation therapy in first-line large B-cell lymphoma patients. Allogene anticipates that an interim futility analysis is on track for Q2 2026. Our partnership with Iovance is another powerful signal to reach any versatility of our platform. Iovance is advancing IOV-4001 in PD-1 inactivated tumor infiltrating lymphocytes or TIL cell therapy. In previously treated advanced melanoma patients, leveraging our gene editing capacity, clinical results of IOV-4001 in melanoma are anticipated this year.
R&D activities continue to advance under our research and collaboration agreement with AstraZeneca, which leverages Cellectis' gene editing expertise and manufacturing capabilities to develop up to 10 novel cell and gene therapy products for areas of high unmet medical need, including oncology, immunology and rare genetic disorders. Partnership is a further testament to the industrial credibility of our gene editing platform and our manufacturing capabilities. 2026 will be a year of data of milestones and of momentum for Cellectis. We are grateful for your continued trust and support. We look forward to updating you through the year as we execute against each of these milestones. With that, I would like to turn the call over to Dr. Adrian Kilcoyne, our Chief Medical Officer, who will provide further details on our clinical programs. Adrian, please go ahead.
Thank you, Andre. I will provide a focused clinical perspective on our lasme-cel and eti-cel programs. The Phase I BALLI-01 study of lasme-cel in third line and beyond acute lymphoblastic leukemia enrolled 40 patients with confirmed at least 70% CD22 expression. These patients were heavily pretreated with a median of 4 prior lines of therapy. The median number of prior lines of therapy at the recommended Phase II dose was higher at 5. These heavily pretreated patients have already relapsed following multiple targeted therapies. Most patients have been previously treated with blinatumomab and relapsed.
Approximately 50% have also relapsed following CD19 CAR T and alemtuzumab, a CD22 directed antibody drug conjugate.
Therefore, there remains very few, if any, therapeutic options for these patients. At the recommended Phase II dose, lasme-cel achieved an overall response rate of 83% and a CR/CRi rate of 42%. In the target Phase II population with an upper age cutoff of 50 years old, response rates were even higher with 100% overall response and a CR/CRi rate of 56%. Importantly, of those subjects who achieved a CR/CRi, 80% achieved MRD-negative status. Additionally, of the 9 patients in the target Phase II population, all became transplant eligible with 7 of 9 receiving stem cell transplant at the time of data cutoff.
This is a very positive outcome for these patients. In patients who achieved MRD-negative , median overall survival was 14.8 months, a meaningful survival benefit in this heavily pretreated population. The safety profile of lasme-cel was favorable and similar or lower than observed with other autologous CAR T therapies. Greater than or equal to Grade 3 cytokine release syndrome occurred in 2.5% of patients and greater than or equal to Grade 3 ICANS occurred in 5% of patients at the recommended Phase II dose. The full Phase I data has been submitted for presentation at the 2026 European Hematology Association Congress to be held in Stockholm in June.
The Phase I program also addressed 2 important additional questions. The first is whether our internally manufactured product could result in similar or indeed improved efficacy compared to product manufactured by an external CDMO. The second is whether alemtuzumab as part of the preconditioning lymphodepletion regimen results in superior lasme-cel expansion and therefore, efficacy compared to the standard lymphodepletion regimen. Validating our decision to internalize our manufacturing capabilities, Cellectis' manufactured product demonstrated meaningfully higher response rates than external CDMO manufactured product with overall response rates of 68% and 28%, respectively. Secondly, the data demonstrated that increased alemtuzumab exposure correlates with improved response. These data were outlined at the American Society of Hematology Annual Conference in December 2025.
Additional data have also been submitted for presentation at the 2026 European Hematology Association Congress. We are now enrolling in the pivotal Phase II program focused on the target Phase II population of patients aged between 12 and 50 years of age. We are accelerating site opening and are on track to reach our goal of approximately 75 recruiting centers across Europe and North America. As Andre highlighted, we expect to complete the first interim analysis of 40 patients in Q4 2026. These data will be shared publicly in a forum to be determined. I will remind you that as previously disclosed, the anticipated BLA submission is planned for the second half of 2028.
Our second ongoing program investigating our dual CAR asset, eti-cel, targets CD20 and CD22 expressing tumors in third line and beyond non-Hodgkin's lymphoma. This highly differentiated product offering important and much needed alternative targets of CD19 continues in Phase I. The preliminary Phase I data presented at ASH 2025 showed an 88% overall response rate and a 63% complete response rate at the current dose level in the 8 evaluable patients. Cellectis believes we can further enhance these already high response rates through the addition of low-dose IL-2 support. The addition of low-dose IL-2 offers the potential to further enhance CAR T expansion, tumor killing and persistence without negatively impacting toxicities.
We expect to present the Phase I data set, including the IL-2 cohort results later this year. We plan to progress this program to pivotal Phase II in 2027 and anticipate a BLA submission in H2 2029. As you can see, 2026 promises to be an exciting year for Cellectis with a number of critical milestones and catalysts as we transform into a late-stage development organization. I look forward to sharing our progress later this year. With that, I would like to hand the call over to Arthur Stril, Cellectis' Chief Financial Officer and Chief Business Officer, for an overview of our financials for the fourth quarter and full year 2025. Arthur, over to you.
Thank you, Adrian. Let me now walk you through our financial position. As Andre mentioned, we have managed our cash with discipline over the past year, focusing our spend on what matters most. The development of lasme-cel and eti-cel and the operation of our end-to-end manufacturing facilities in Paris and Raleigh. We believe our current cash position gives us the financial runway to execute on our pivotal Phase II program for lasme-cel and our Phase I for eti-cel and delivered 2 key readouts in Q4 2026. The first interim analysis with 40 patients for lasme-cel and the full Phase I data set for eti-cel . We are well positioned financially to execute on these 2 trials as our cash, cash equivalents and fixed term deposits as of December 31, 2025, remain sufficient to fund our operations into H2 2027.
We are also looking forward to the upcoming data readouts for our partner programs, in particular, Servier and Allogene cema-cel in April 2026 and Iovance's IOV-4001 this year as well. Finally, we are excited that activities are progressing under our strategic collaboration with AstraZeneca, which has positively impacted our 2025 revenue. As of December 31, 2025, our cash, cash equivalents, restricted cash and fixed term deposits classified as current financial assets amount to $211 million compared to $264 million as of December 31, 2024.
This $53 million decrease is mainly due to $36.9 million cash in from revenue, $8.4 million of interest received from our financial and cash equivalent investments, partially offset by cash payments from Cellectis to suppliers of $50.5 million. Cellectis wages, bonuses and social expenses paid of $40 million, the payments of lease debts of $11 million and the repayment of the PGE loan of $5.4 million. You are invited to refer to our press release for figures related to consolidated net loss attributable to shareholders of Cellectis for the 12 months ended December 31, 2025. We very much look forward to a rich 2026, especially with Servier and Allogene's readout for cema-cel next month and our 2 readouts for lasme-cel and eti-cel later this year. We'll now turn the call over to the operator for questions.
[Operator Instructions] Our first question will come from Amin Makarem with Jefferies.
2. Question Answer
Two from us. First, on the lasme-cel and the BALLI-01 enrollment. How is recruitment tracking in the pivotal study? And when do you expect to complete enrollment for the dose selection portion? And I have a follow-up.
Yes. Thanks, Amin. I can take that. Currently, we're doing very well. We're engaging many sites. Site opening is on track. We're certainly on track to complete our data analysis by the end of the year. So that's just for the other people on the call, that's the first 40 patients interim analysis, and that's part of the dose optimization phase of the study, looking at 2 alternative doses of alemtuzumab, which is required by CDER. So yes, it's going well, and we're on track for Q4 data sharing.
And for this dose optimization portion, as you evaluate the 2 alemtuzumab dose levels, what are the expectations? What differences should we expect between the 2 arms in terms of efficacy signal? Or are you expecting a meaningful difference in the safety? Or do you think the 2 arms are going to be generally in the same ballpark?
We don't -- it's very difficult to say, and almost require a crystal ball to decide will there be a big difference in terms of both. We anticipate, however, that we have designed a very strong analysis plan to allow us to differentiate between the 2 components. That will be based on efficacy, safety, but also significantly important translational markers in terms of our CAR T expansion, host T-cell reconstitution, et cetera. So we do believe that we will be able to define an optimized dose by the end of the year. We don't think that will be a significant challenge. However, we know that both of these doses of alemtuzumab, very importantly, they work. It's all about dose optimization now. It's not about finding an effective dose.
Our next question will come from Salveen Richter with Goldman Sachs.
Two questions from us. One is, could you provide more details on the Servier arbitration given the ruling that you have to engage in discussions with Allo regarding the direct licensing of 501? And help us understand how this impacts your eligibility for the $340 million in milestones into this interim data? And then secondly, could you talk about your decision to include CD52 preconditioning in both the studies in the context of safety as we see some of the competitors moving away from CD52.
Salveen, this is Arthur. Thanks for the question. I'll take the question on the arbitration and then hand it over to Adrian for the clinical question. So just as a reminder, so the arbitral decision of December 2025 ruled on the partial termination of the license agreement. with respect to one product, which is UCART19 V1, also named ALLO-501 by Allogene. So this product has been brought back to Cellectis, and we are free to develop it or moving forward.
The tribunal did not affect ALLO-501A or cema-cel. So we remain fully eligible for up to $340 million in development and sales milestones. That is obviously under the Servier agreement, which has been then sublicensed to Allogene. So this does not impact any eligibility to upcoming development and sales milestone as well as royalties down the line on cema-cel, but it gave us back UCART19 or ALLO-501 and we're free to do whatever we would like to do with it. And I will hand it over to Adrian for the clinical question.
One thing I'd like to add, like during our thinking is that once you -- like the pivotal trial is effective, then the milestone should be triggered. So we're definitely expecting to have this $20 million milestone paid one day.
Okay. I'll answer the alemtuzumab question. It's a great question. There's a few things -- just a few observations from our studies. One is that alemtuzumab is really important to optimize lymphodepletion. And as I said earlier, the more optimal lymphodepletion, the better the outcomes in terms of responses. You get a much deeper response. As part of our Phase I program, we did test a lymphodepletion regimen without alemtuzumab, and we failed to get any MRD-negative responses. So we know that alemtuzumab is very effective.
The second part is you're saying some people are moving away from it. Now we believe, as I've said already, alemtuzumab is important, but we also believe that it's critically important that you get the right dose. It's like everything too much is always too much. So we have -- compared to other companies that are using alemtuzumab or alemtuzumab similars, we're using a much lower dose. We spent a lot of time already optimizing our doses. So we believe we've got the right balance between optimal efficacy, mitigating the risks that may be associated with that more enhanced lymphodepletion regimen. But also, let's not forget that alemtuzumab has been widely used in other clinical context. So it's got a very well-characterized safety profile, and we've been able to build into all our protocols very extensive risk mitigation. So we believe we've got the right strategy with our alemtuzumab. I cannot answer why others may have transitioned away from it.
Our next question will come from Jack Allen with Baird.
Congrats to the team on all the progress. I guess the first one I wanted to ask was on eti-cel and how we should think about the update in the fourth quarter of this year. Any additional color you're willing to provide as it relates to the breadth of the update and number of patients and the durability of follow-up there would be great. And then I have a quick follow-up as well.
I can give you a top line update on top of the data we already have. As we've shared already at our current dose level, we're seeing a 63% complete remission rates, 88% overall response rates. By the end of the year, you will see data in cohorts with and without IL-2. Now we would acknowledge that 63% complete remission rate is actually a very strong result. And theoretically, we do not need to enhance that further, but we want to. We believe we can with the addition of low-dose IL-2. So by the end of the year, you will see -- we're currently expanded at our recruiting sites rather significantly we've doubled them. So we anticipate we will be able to get a reasonable -- and I cannot give you a number because I don't know what the recruitment rates are going to be. But we will be towards the latter part of the year also not in the staggering phase.
So we would anticipate a significant increase in recruitment. You will see some durability data is what you asked about. But of course, for the patients in the later phase, there will hopefully be good durability signals. We have in our mind the durability levels we want to achieve, and it's around the 6-month mark. But hopefully, by the end of the year, you'll be able to see a very clear picture. I think the efficacy question has already been answered. The question is, can we enhance it even further into the 70s rather than in the mid-60s. But also, it will give us a very good signal is to -- is IL-2 really a potential game changer for allogeneic therapy. We obviously based on our preclinical data, which is going to be presented at AACR and again, some at EHA that we believe it could offer a really, really a fundamental improvement for allogeneic cell therapies.
Great. And then we might be getting ahead of ourselves a little bit here. But on lasme-cel and the commercial opportunity there, I was wondering if you've been looking at Aucatzyl from Autolus. And if you have any thoughts around the initial commercial launch of that CD19 allo therapy in ALL.
I can give it from a medical perspective, and Arthur, maybe you want to talk a bit more broadly on the commercial opportunity. Let's not forget, our patients are generally post-CD19 failures. So we don't -- we are not seeing this as a competition. We have a very differentiated target CD22. We believe the market is pretty saturated with CD19. It's not to Aucatzyl isn't a very good product. It is. Their data is very strong. But these patients are very difficult to treat.
Many of them will relapse and they need to have an alternative target. So we believe that this is not a competing product, but actually a very differentiated one. In terms of market size, you may be aware, we're starting to look at earlier lines of therapy. We will have data starting to be generated next year on that frontline consolidation, very much aligned with what Allogene has done, which we think is a fantastic idea in the non-Hodgkin's lymphoma place. We will be looking at that in the ALL space. So we believe that's a really important part for those incredibly difficult to treat patients frontline.
I can add, I think from a commercial launch perspective, you absolutely cannot compare an autologous launch to an allogeneic launch. And I think the 2 primary differences is, one, you need to have leukapheresis access for the patients, and this is slow. This is very competitive, and this is controlled by hospitals, not by the pharma companies, whereas obviously, with off-the-shelf, we will have manufactured a huge number of doses in advance so that at the time of launch, we can address all our clinical centers immediately without having to set up these cumbersome logistics aspect.
And the second thing, obviously, is because of our off-the-shelf nature, we have very significant economies of scale, and we see it even at the pivotal stage, which will allow us to get extremely competitive gross margins and gross margin, which was much more the types of what pharma is now used to with small molecules and antibodies, whereas pricing of autologous has been difficult because of the significant cost of goods that make a very important impact on the margin. So I think the fact that we're off-the-shelf will allow us for a much smoother launch in terms of pure access due to the off-the-shelf nature and also in a much more economically competitive aspect due to the economies of scale and the very favorable gross margins. So I don't think Aucatzyl will be a very good comparator there.
One thing I'd like to add, Jack, one thing that was interesting. I was like recently visiting a clinical center we're working with for acute lymphoblastic leukemia with Adrian. And there was one ALL patient that was sitting in the backlog waiting for an available apheresis spot since long time, [indiscernible] with non-Hodgkin lymphoma, DLBCL patient, multiple myeloma patient, autoimmune patient, et cetera. And this patient -- like ALL is a very aggressive disease. And still this stage, I'm not going to say which type of product it was about to be given to him because I don't know. But the fact is that this patient was like in real distress waiting for this like apheresis spot, and this is what you would consider as autologous launch of yet another CD19 autologous CAR T.
Our next question will come from Silvan Tuerkcan with Citizens.
I just wanted to ask if you could just give us a brief recap of what you're expecting at EHA from these 2 programs that you have ongoing? Is it mainly longer follow-up?
So you will be aware that we shared our data at our R&D Day back in October. We, after that, actually added some more patients in because we wanted to do some level of dose optimization in advance of our Phase II program. We wanted to ensure that, that lower dose is an acceptable dose to give to patients. So there are going to be an updated data set, the whole data set, including those additional patients. So it is -- I would consider it a level of progression from the original Phase I package that we presented.
The data are not remarkably different, let me tell you, but it's an important addition to the data. The second thing that you -- we hope -- we're assuming that it will be accepted is really to try and understand what makes a product successful. And again, to build on the question from our Goldman Sachs colleagues, whether we're talking about alemtuzumab is the importance of that preconditioning and that day 0, not only from a level of lymphodepletion, but actually the environment in which you infuse your cells is critically important and in many ways, predicts the outcome. And the fact that we have now identified a really clear picture of optimal lymphodepletion, optimal environment in which you infuse your cells, we are now able to predict very early on our patient is going to respond. So all these data will be shared. So I think we're excited by it so far.
Our next question will come from Sebastiaan van der Schoot with VLK.
So I wanted to ask you how you're looking at the possibility of applying your lymphodepletion procedure in the outpatient setting as well as the allogeneic CAR T. And then maybe can you provide some insight on how the partnership with AstraZeneca is going? Can we expect any updates in the next 24 months?
I can take the first part of that, Arthur, in terms of outpatient setting. Right now, the regulatory authorities require inpatient delivery of products. And I think that's consistent with most autologous therapies as well in the CAR T space. And once there becomes some clinical confidence in how to use, will that transition into the outpatient setting? I think that may be a natural transition. But for that, you need a body of evidence. So hopefully, that will be provided not only by the Phase II program, but also by clinical usage from that.
But again, I think it's a very different offering in that to Arthur's point, we do not leave that leukapheresis, et cetera. So I do think it will take some time for this to be in the outpatient setting. But assuming that we continue to have a fairly reassuring safety profile, there's no real reason why that this cannot in time, transition to the outpatient setting.
And I will take the question on AstraZeneca. So first of all, we're extremely pleased to count AstraZeneca as a strategic partner. As you have seen, they have continued to invest very heavily in the cell and gene therapy space, and they're one of the few companies that are betting very hard not only on cell and gene therapy, but also on off-the-shelf treatments. And I think we're very fortunate to have them as a key shareholder, but also a strategic R&D partner.
The activities are going very well under the collaboration. There's a number of activities ongoing across a range of therapeutic area. Do not expect updates in the short term. This is at the request of AstraZeneca. They are essentially asking us for now to stay reasonably quiet, especially given the competitive nature of certain aspects that we are working on. But definitely, as we continue the dialogue with them around disclosure and as and when the time is right, we will be providing update. And I think you will be interested in seeing what has been brewing with them.
[Operator Instructions] Our next question will come from Yanan Zhu with Wells Fargo.
So first, regarding the lasme-cel pivotal study. I was wondering for the 4Q readout, is the focus there, the 3-month CRi from the 2 arms in that first 40-patient cohort? And then how do you manage the transition from completing that cohort to the start of the enrollment of the 80-patient portion for the optimal alemtuzumab dose, i.e., the final pivotal cohort. Will you be able to start enrolling before you have the data for the comparison of the 2 alemtuzumab cohorts? Yes. And then I have a follow-up.
Great. This has some great questions there. First and foremost, no, the decision for dose optimization is not based on the 3-month CR/CRi. It's actually based on an earlier time cutoff of 8 weeks. And that's important. We will still be looking at efficacy, safety, but all the important translational markers predictive of not only short-term but long-term outcomes, we have those answers by that first 8 weeks. So it's a composite of many of those that we will be presenting. In terms of that transition from that to the longer phase of the study, we have built a lot of flexibility into the protocol to allow us to continue recruiting. So importantly, this does not mean our study has to stop while we're engaging with the regulatory authorities. The recruitment will continue for the remaining [indiscernible] patients.
Great. Very helpful color. And the follow-up is mainly on the competitive landscape in terms of additional modalities in vivo CAR T specifically. Can you talk about the advantages or limitations for that modality or whether you have any interest in moving in that direction at early stage efforts?
I can have an initial thoughts on this. And I think I know that Andre and Arthur also have views on the positioning of in vivo CAR. We're looking at incredibly sick patients with incredibly aggressive disease that need a lot of therapy. We don't believe these very difficult-to-treat tumors will be the definition for in vivo CAR. We think in vivo CAR certainly have a place. But will it be the right therapy for incredibly difficult to treat tumors and incredibly difficult to manage patients? We don't believe so.
So yes, there will be in vivo CAR in some, maybe autoimmune may be a better destination. But any therapy that requires extensive gene editing and extensive patient management will probably -- maybe it will be a bridge too far for in vivo CAR. And I know, Andre, you have a view on this as well.
Think the process like in vivo CAR is similar to autologous CAR T. The only thing it allows is essentially try to leapfrog apheresis, which is a great thing. It's like it's a huge market access option that is given here. Nevertheless, it will still be totally linked to the fitness of the cells of the patient or their presence. So if it doesn't respond to blina, if you can't do an autologous, then you go for in vivo, well, if the cells are not really very well functional, it's not going to work anymore because you need the T cells to be fit. That's one point.
The second point is it will also be very much related to the current malignancies that are treated, which is essentially liquid tumors, B-cell malignancies or multiple myeloma. But the spread of this into solid tumor is going to be different. And finally, like there's a lot of papers that are coming out, like a lot of cells are transduced by these vectors that are not T cells. So like you need to restrict at the time. I think these technologies are going to come in the coming future, to try to restrict the cells to what needs to be transduced by the in vivo CAR T and not to go and deliver.
For example, I've seen a paper recently that shows more vector inside, for example, hepatic cells expressing CAR and then in T cells. So if you do this worldwide like really broadband, then the questions at a time. And also like the genome is only 6.4 billion base pairs, like 23, 2x chromosomes. If you inject trillions and trillions of vectors in hundreds of patients or thousands of patients, it's like I hope that this will be safely integrated. If you go, for example, with autologous CAR T, you can master exactly when the cells are transduced. If you go for an allogeneic CAR, you have all the QC that lasts a long period of time to show that everything is totally square. If you make the product in vivo, which is the case here, then you have to master how the product is made and not to have a lot of byproducts all around the place. So that's like the initial concern. But I'm sure that this will be solved in coming decades.
And at this time, there are no further questions in the queue. So I'll turn the meeting back over to our speakers for any additional or closing remarks.
Thank you very much, everyone. I really appreciate all the questions here. As you can see, this will be a very exciting year 2026 with a number of updates from our partners and from ourselves. And I think we are poised for a new dawn of allogeneic CAR T cell therapy. So stay tuned for more updates and looking forward to further discussions as our progress unfolds this year. Thank you very much.
Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.
Transkripte auf Deutsch freischalten
- Alle Event Transkripte auf Deutsch
- Sofortige Übersetzung
- KI-Zusammenfassungen für die wichtigsten Insights
Finanzdaten von Cellectis SA Sponsored ADR
Umsatz
Der Umsatz stellt die Summe aller Einnahmen eines Unternehmens z. B. für dessen Produkte oder Dienstleistungen dar.
Umsatz (TTM) einfach erklärtDirekte Kosten
Direkte Kosten sind die Kosten, die direkt im Zusammenhang mit der Herstellung des Produkts oder der Dienstleistung entstehen.
Bruttoertrag
Der Bruttoertrag gibt an, wie viel vom Umsatz nach Abzug der direkten Herstellkosten im Unternehmen verbleibt. Berechnet man den prozentualen Anteil vom Umsatz, spricht man von der Bruttomarge (engl. Gross Margin).
Brutto Marge einfach erklärtVertriebs- und Verwaltungskosten
Die Vertriebs- & Verwaltungskosten (engl. Selling, General & Administrative expenses, kurz SG&A) beinhalten alle Aufwände für Marketing und den Verkauf sowie die allgemeine Verwaltung des Unternehmens.
Forschungs- und Entwicklungskosten
Die Forschungs- und Entwicklungskosten (engl. research & development costs, kurz R&D) geben Auskunft darüber, wie viel das Unternehmen in die Forschung und die Entwicklung seiner Produkte investiert. Vor allem prozentual vom Umsatz und im Vergleich zu direkten Wettbewerbern sind die Kosten interessant.
EBITDA
Das EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) ist der Gewinn des Unternehmens vor Zinsen, Steuern und Abschreibungen. Berechnet man den prozentualen Anteil vom Umsatz, spricht man von der EBITDA-Marge.
Abschreibungen
Abschreibungen stellen Wertminderungen von Vermögensgegenständen des Unternehmens dar (z.B. durch Abnutzung von Maschinen).
EBIT (Operatives Ergebnis)
Das EBIT (engl. Earnings Before Interest and Taxes) ist der Gewinn des Unternehmens vor Zinsen und Steuern, das auch als operatives Ergebnis bezeichnet wird. Berechnet man den prozentualen Anteil vom Umsatz, spricht man von
der EBIT-Marge.
Nettogewinn
Der Nettogewinn stellt den Gewinn oder Verlust nach Abzug aller Kosten dar.
Nettogewinn einfach erklärtaktien.guide Premium
| Sep '26 |
+/-
%
|
||
| Umsatz | 77 77 |
32 %
32 %
100 %
|
|
| - Direkte Kosten | - - |
-
-
|
|
| Bruttoertrag | - - |
-
-
|
|
| - Vertriebs- und Verwaltungskosten | 16 16 |
14 %
14 %
21 %
|
|
| - Forschungs- und Entwicklungskosten | 72 72 |
10 %
10 %
93 %
|
|
| EBITDA | -85 -85 |
-
-111 %
|
|
| - Abschreibungen | 55 55 |
-
72 %
|
|
| EBIT (Operatives Ergebnis) EBIT | -141 -141 |
176 %
176 %
-183 %
|
|
| Nettogewinn | -145 -145 |
89 %
89 %
-188 %
|
|
Angaben in Millionen USD.
Nichts mehr verpassen! Wir senden Dir alle News zur Cellectis SA Sponsored ADR-Aktie direkt und kostenlos in Deine Mailbox.
Auf Wunsch erhältst Du jeden Morgen pünktlich zum Frühstück eine E-Mail, die alle für Dich relevanten Aktien-News enthält.
Cellectis SA Sponsored ADR Aktie News
Firmenprofil
Cellectis SA ist ein biopharmazeutisches Unternehmen, das sich mit der Forschung und Entwicklung von Genom-Engineering-Technologie beschäftigt. Das Unternehmen ist in den folgenden Segmenten tätig: Therapeutika und Pflanzen. Das Segment Therapeutika konzentriert sich auf die Entwicklung von Produkten im Bereich der Immun-Onkologie und von neuartigen Produkten ausserhalb der Immun-Onkologie zur Behandlung anderer menschlicher Krankheiten. Das Segment Pflanzen konzentriert sich auf die Anwendung seiner Geneditierungstechnologien zur Entwicklung von Pflanzenprodukten der neuen Generation im Bereich der landwirtschaftlichen Biotechnologie durch eigene Anstrengungen oder durch Allianzen mit anderen Unternehmen auf dem Agrarmarkt. Seine therapeutischen Produkte befinden sich noch im präklinischen Stadium, das für verschiedene Arten von Tumoren entwickelt wird. Cellectis wurde am 20. Februar 1999 von David J. Sourdive und André Choulika gegründet und hat seinen Hauptsitz in Paris, Frankreich.
aktien.guide Premium
| Hauptsitz | Frankreich |
| CEO | Dr. Choulika |
| Mitarbeiter | 227 |
| Gegründet | 1999 |
| Webseite | www.cellectis.com |


